{"content":"<li class=\"n-box-item date-title\" data-end=\"1552967999\" data-start=\"1552881600\" data-txt=\"Monday, December 23, 2019\">Monday, March 18, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3443893\" data-ts=\"1552949666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRBP\" target=\"_blank\">CRBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443893-corbusplus-6_3-oppenheimer-sees-big-potential-in-lead-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corbus +6.3% as Oppenheimer sees big potential in lead candidate</a></h4><ul>   <li>Clinical-stage Corbus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a>) is <font color=\"green\">up 6.3%</font> after hours following its start at Outperform by Oppenheimer.</li>    <li>Its lead product candidate, lenabasum, has had positive prior clinical data in multiple settings, the firm says -- each of which could offer $500M-$1B in potential sales. The next 12-24 months will be transformational, according to the note, as late-stage trials deliver initial data. (h/t Bloomberg)</li>    <li>Lenabasum is a synthetic oral endocannabinoid that's in Phase 3 trial for treatment of systemic sclerosis and dermatomyositis, and in Phase 2 trial to treat systemic lupus erythematosus and cystic fibrosis.</li>    <li>Oppenheimer has a price target of $28, implying 300% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443893\" data-linked=\"Corbus +6.3% as Oppenheimer sees big potential in lead candidate\" data-tweet=\"$CRBP - Corbus +6.3% as Oppenheimer sees big potential in lead candidate https://seekingalpha.com/news/3443893-corbusplus-6_3-oppenheimer-sees-big-potential-in-lead-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3443893-corbusplus-6_3-oppenheimer-sees-big-potential-in-lead-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443890\" data-ts=\"1552948790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECPG\" target=\"_blank\">ECPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443890-encore-capitalminus-3_4-on-report-of-1_5m-share-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Encore Capital -3.4% on report of 1.5M-share secondary</a></h4><ul>   <li>Encore Capital Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ECPG' title='Encore Capital Group, Inc.'>ECPG</a>) is <font color=\"red\">3.4% lower</font> postmarket after Bloomberg reported a secondary offering of 1.5M shares.</li>    <li>Those are expected to come at $30.65-$31.10 per share, a discount of 3.1% to 4.5%.</li>    <li>The seller is unknown but more than 10 holders have at least 1.5M shares, Bloomberg notes. Some 30.9M shares are outstanding.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443890\" data-linked=\"Encore Capital -3.4% on report of 1.5M-share secondary\" data-tweet=\"$ECPG - Encore Capital -3.4% on report of 1.5M-share secondary https://seekingalpha.com/news/3443890-encore-capitalminus-3_4-on-report-of-1_5m-share-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/3443890-encore-capitalminus-3_4-on-report-of-1_5m-share-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443888\" data-ts=\"1552948276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VERU\" target=\"_blank\">VERU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443888-veruplus-6_3-oppenheimer-starts-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veru +6.3% as Oppenheimer starts at Outperform</a></h4><ul>   <li>Biopharma Veru (NASDAQ:<a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a>) is <font color=\"green\">up 6.3%</font> after hours following a start at Outperform by Oppenheimer.</li>    <li>The stock is \"off the radar,\" analyst Leland Gershell writes, but mid-2019 readouts on zuclomiphene and VERU-111 will catalyze investor attention. And the stock is an outlier in small-cap biopharmaceuticals since it generates commercial revenue that meaningfully offsets R&amp;D. (h/t Bloomberg)</li>    <li>Gershell's price target is $5, implying 250% upside from today's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443888\" data-linked=\"Veru +6.3% as Oppenheimer starts at Outperform\" data-tweet=\"$VERU - Veru +6.3% as Oppenheimer starts at Outperform https://seekingalpha.com/news/3443888-veruplus-6_3-oppenheimer-starts-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3443888-veruplus-6_3-oppenheimer-starts-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443884\" data-ts=\"1552946302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REV\" target=\"_blank\">REV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443884-revlonminus-10-after-wide-q4-miss-finds-material-weakness-in-internal-controls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revlon -10% after wide Q4 miss, finds &#39;material weakness&#39; in internal controls</a></h4><ul><li>Revlon (NYSE:<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a>) <font color=\"red\">-10.1%</font> after-hours as it posts a <a href=\"https://seekingalpha.com/news/3443818-revlon-misses-1_01-misses-revenue\" target=\"_blank\">Q4 loss</a>, missing expectations for a profit by a wide margin, and says it needs additional time to file its 2018 Form 10-K after identifying a \"material weakness\" in its internal controls over financial reporting.</li><li>REV, which expects to file the 10-K no later than March 29, says the problem relates primarily to the lack of design and maintenance of effective controls in connection with the previously disclosed implementation of its enterprise resource planning system in the U.S.</li><li>REV says its 5.7% Y/Y decline in Q4 net sales was driven by several one-time items including lower net sales in the Revlon segment due in part to the shift in timing of customer resets from Q4 2018 into late Q1 2019 and lower net sales in the fragrances segment driven by several expired brand licenses in 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443884\" data-linked=\"Revlon -10% after wide Q4 miss, finds &#39;material weakness&#39; in internal controls\" data-tweet=\"$REV - Revlon -10% after wide Q4 miss, finds &#39;material weakness&#39; in internal controls https://seekingalpha.com/news/3443884-revlonminus-10-after-wide-q4-miss-finds-material-weakness-in-internal-controls?source=tweet\" data-url=\"https://seekingalpha.com/news/3443884-revlonminus-10-after-wide-q4-miss-finds-material-weakness-in-internal-controls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443876\" data-ts=\"1552945151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443876-stne-synh-rev-and-wage-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STNE, SYNH, REV and WAGE among notable after hour movers</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/STNE' title='StoneCo Ltd.'>STNE</a> <font color=\"green\">+12.72%</font>. <a href='https://seekingalpha.com/symbol/SYNH' title='Syneos Health, Inc.'>SYNH</a> <font color=\"green\">+8.6%</font>. <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color=\"green\">+6.84%</font>. <a href='https://seekingalpha.com/symbol/WWE' title='World Wrestling Entertainment, Inc.'>WWE</a> <font color=\"green\">+4.99%</font>. <a href='https://seekingalpha.com/symbol/LSI' title='Life Storage, Inc.'>LSI</a> <font color=\"green\">+4.99%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a> <font color=\"red\">-12.66%</font>. <a href='https://seekingalpha.com/symbol/WAGE' title='WageWorks, Inc.'>WAGE</a> <font color=\"red\">-5.26%</font>. <a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a> <font color=\"red\">-5.23%</font>. <a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color=\"red\">-5%</font>. <a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a> <font color=\"red\">-4.99%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443876\" data-linked=\"STNE, SYNH, REV and WAGE among notable after hour movers\" data-tweet=\"$STNE $SYNH $CRBP - STNE, SYNH, REV and WAGE among notable after hour movers https://seekingalpha.com/news/3443876-stne-synh-rev-and-wage-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443876-stne-synh-rev-and-wage-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443870\" data-ts=\"1552944738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443870-ffin-moving-to-midcap-400-foeplus-2-on-move-to-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FFIN moving to MidCap 400; FOE +2% on move to SmallCap 600</a></h4><ul>   <li>First Financial Bankshares (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIN' title='First Financial Bankshares, Inc.'>FFIN</a>) is <a href=\"https://www.spice-indices.com/idpfiles/spice-assets/resources/public/documents/894365_firstfin4fer6.pdf?force_download=true\" target=\"_blank\">moving up into the S&amp;P MidCap 400</a>.</li>    <li>It's replacing MB Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/MBFI' title='MB Financial, Inc.'>MBFI</a>) in the MidCap 400, with that firm set to be acquired by S&amp;P 500 constituent Fifth Third.</li>    <li>Meanwhile, Ferro (NYSE:<a href='https://seekingalpha.com/symbol/FOE' title='Ferro Corporation'>FOE</a>) is taking First Financial's place in the SmallCap 600; its shares are <font color=\"green\">up 2%</font> after hours.</li>    <li>The moves are effective prior to the market open on Friday, March 22.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443870\" data-linked=\"FFIN moving to MidCap 400; FOE +2% on move to SmallCap 600\" data-tweet=\"$FFIN $MBFI $FOE - FFIN moving to MidCap 400; FOE +2% on move to SmallCap 600 https://seekingalpha.com/news/3443870-ffin-moving-to-midcap-400-foeplus-2-on-move-to-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3443870-ffin-moving-to-midcap-400-foeplus-2-on-move-to-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443855\" data-ts=\"1552943484\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YEXT\" target=\"_blank\">YEXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443855-yext-falls-on-proposed-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yext falls on proposed stock offering</a></h4><ul><li>Yext (NYSE:<a href='https://seekingalpha.com/symbol/YEXT' title='Yext, Inc.'>YEXT</a>) <a href=\"https://seekingalpha.com/pr/17447617-yext-announces-proposed-offering-common-stock\" target=\"_blank\">announces</a> an underwritten public offering of 6.1M shares of common stock.</li><li>Underwriters have a 30-day option to purchase up to an additional 900K shares.</li><li>Yext shares are <font color=\"red\">down 2.6%</font> after hours to $22.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443855\" data-linked=\"Yext falls on proposed stock offering\" data-tweet=\"$YEXT - Yext falls on proposed stock offering https://seekingalpha.com/news/3443855-yext-falls-on-proposed-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3443855-yext-falls-on-proposed-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443844\" data-ts=\"1552942700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIZ\" target=\"_blank\">AIZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443844-assurantminus-1_9-tpg-global-sheds-rest-of-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Assurant -1.9% as TPG Global sheds rest of stake</a></h4><ul><li>Assurant (NYSE:<a href='https://seekingalpha.com/symbol/AIZ' title='Assurant, Inc.'>AIZ</a>) announces a secondary public offering of all of the remaining 7.87M shares of its common stock held by certain affiliates of TPG Global.</li><li>Assurant <font color=\"red\">falls 1.9%</font> in after-hours trading.</li><li>The shares were originally part of the 10.1M shares issued to certain affiliates of TPG Global for the purchase of the Warranty Group in May 2018.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3442743-assurant-plans-1_35b-capital-return-2021\" target=\"_blank\">Assurant plans ~$1.35B of capital return through 2021</a> (March 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443844\" data-linked=\"Assurant -1.9% as TPG Global sheds rest of stake\" data-tweet=\"$AIZ - Assurant -1.9% as TPG Global sheds rest of stake https://seekingalpha.com/news/3443844-assurantminus-1_9-tpg-global-sheds-rest-of-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3443844-assurantminus-1_9-tpg-global-sheds-rest-of-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443843\" data-ts=\"1552942622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSTG\" target=\"_blank\">NSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443843-nanostring-files-for-mixed-shelf-offering-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NanoString files for mixed shelf offering; shares down 2% after hours</a></h4><ul><li>NanoString Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/NSTG' title='NanoString Technologies, Inc.'>NSTG</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1401708/000140170819000078/nstg-s3asr.htm\" target=\"_blank\">prospectus </a>for an unspecified mixed shelf offering.</li><li>Shares are down <font color=\"red\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443843\" data-linked=\"NanoString files for mixed shelf offering; shares down 2% after hours\" data-tweet=\"$NSTG - NanoString files for mixed shelf offering; shares down 2% after hours https://seekingalpha.com/news/3443843-nanostring-files-for-mixed-shelf-offering-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3443843-nanostring-files-for-mixed-shelf-offering-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443825\" data-ts=\"1552941624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AQB\" target=\"_blank\">AQB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443825-aquabounty-down-11-after-hours-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AquaBounty down 11% after hours on equity offering</a></h4><ul><li>AquaBounty Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AQB' title='AquaBounty Technologies, Inc.'>AQB</a>) slips <font color=\"red\">11%</font> after hours in response to its planned <a href=\"https://seekingalpha.com/pr/17447461-aquabounty-technologies-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">stock offering</a>. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443825\" data-linked=\"AquaBounty down 11% after hours on equity offering\" data-tweet=\"$AQB - AquaBounty down 11% after hours on equity offering https://seekingalpha.com/news/3443825-aquabounty-down-11-after-hours-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3443825-aquabounty-down-11-after-hours-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443823\" data-ts=\"1552941511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNH\" target=\"_blank\">SYNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443823-syneos-health-beats-0_13-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syneos Health beats by $0.13,  revenue in-line</a></h4><ul><li>Syneos Health (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNH' title='Syneos Health, Inc.'>SYNH</a>): Q4 Non-GAAP EPS of $0.95 <span style=\"color:green\">beats by $0.13</span>; GAAP EPS of $0.44.</li><li>Revenue of $1.15B (+6.5% Y/Y) in-line.</li><li>Shares <font color=\"green\">+8.6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17447577-syneos-health-reports-fourth-quarter-full-year-2018-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443823\" data-linked=\"Syneos Health beats by $0.13,  revenue in-line\" data-tweet=\"$SYNH - Syneos Health beats by $0.13, revenue in-line https://seekingalpha.com/news/3443823-syneos-health-beats-0_13-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3443823-syneos-health-beats-0_13-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443822\" data-ts=\"1552941424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRS\" target=\"_blank\">AMRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443822-amyris-up-20-after-hours-on-300m-cannabis-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyris up 20% after hours on $300M cannabis deal</a></h4><ul><li>Amyris (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a>) is up <font color=\"green\">20%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17447563-amyris-finalizes-cannabinoid-development-licensing-commercialization-agreement-containing-300\" target=\"_blank\">agreement </a>with a newly formed company called LAVVAN aimed at cannabinoid development, licensing and commercialization that, it says, contains as much as $300M in R&amp;D and milestone payments plus long-term royalties.</li><li>It believes that it can earn a \"significant portion\" of the milestones by the end of 2020, including $20M - 30M this year.</li><li>Under the terms of the deal, LAVVAN, backed by unnamed leaders in the pharmaceutical, cannabis and financial sectors, will be responsible for global manufacturing and commercialization. Additional financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443822\" data-linked=\"Amyris up 20% after hours on $300M cannabis deal\" data-tweet=\"$AMRS - Amyris up 20% after hours on $300M cannabis deal https://seekingalpha.com/news/3443822-amyris-up-20-after-hours-on-300m-cannabis-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3443822-amyris-up-20-after-hours-on-300m-cannabis-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443818\" data-ts=\"1552941306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REV\" target=\"_blank\">REV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443818-revlon-misses-1_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revlon misses by $1.01, misses on revenue</a></h4><ul><li>Revlon (NYSE:<a href='https://seekingalpha.com/symbol/REV' title='Revlon, Inc.'>REV</a>): Q4 Non-GAAP EPS of -$0.86 <span style=\"color:red\">misses by $1.01</span>; GAAP EPS of -$1.33.</li><li>Revenue of $741.6M (-5.7% Y/Y) <font color=\"red\">misses by $7.7M</font>.</li><li>Shares <font color=\"green\">+2.33%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17447585-revlon-reports-fourth-quarter-full-year-2018-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443818\" data-linked=\"Revlon misses by $1.01, misses on revenue\" data-tweet=\"$REV - Revlon misses by $1.01, misses on revenue https://seekingalpha.com/news/3443818-revlon-misses-1_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443818-revlon-misses-1_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443815\" data-ts=\"1552941188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STNE\" target=\"_blank\">STNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443815-stonecoplus-8_1-after-q4-revenue-and-income-doubles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">StoneCo +8.1% after Q4 revenue and income more than doubles</a></h4><ul><li>StoneCo (NASDAQ:<a href='https://seekingalpha.com/symbol/STNE' title='StoneCo Ltd.'>STNE</a>) <font color=\"green\">jumps 8.1%</font> in after-hours trading after<a href=\"https://seekingalpha.com/pr/17447508-stoneco-reports-fourth-quarter-fiscal-year-2018-financial-results\" target=\"_blank\"> Q4 total net revenue and income</a> more than doubled to R$529.4M (US$139.6M) from R$247.8M in the year-ago quarter.</li><li>Q4 total payment volume of R$26.6B rose 74% from R$15.3B a year earlier and number of active clients more than doubled to 267.9K from 131.2K.</li><li>Q4 adjusted net income of R$155.9M surged from R$20.9M a year earlier.</li><li>Q4 adjusted free cash flow of R$144.7M vs. loss of R$22.1M a year ago.</li><li><a href=\"https://investors.stone.co/\" target=\"_blank\">Conference call </a>at 5:00 PM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443780-stoneco-reports-q4-results\" target=\"_blank\">StoneCo reports Q4 results</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443815\" data-linked=\"StoneCo +8.1% after Q4 revenue and income more than doubles\" data-tweet=\"$STNE - StoneCo +8.1% after Q4 revenue and income more than doubles https://seekingalpha.com/news/3443815-stonecoplus-8_1-after-q4-revenue-and-income-doubles?source=tweet\" data-url=\"https://seekingalpha.com/news/3443815-stonecoplus-8_1-after-q4-revenue-and-income-doubles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443814\" data-ts=\"1552941071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWO\" target=\"_blank\">TWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443814-two-harbors-raising-capital-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two Harbors raising capital; shares down 3%</a></h4><ul><li>Two Harbors (NYSE:<a href='https://seekingalpha.com/symbol/TWO' title='Two Harbors Investment Corp.'>TWO</a>) launches an 18M share secondary offering, with 2.7M share greenshoe for underwriters Credit Suisse, JPMorgan, and JMP Securities.</li><li>Shares are <font color=\"red\">down 3% </font>after hours.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17447535-b-two-b-harbors-investment-corp-announces-public-offering-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443814\" data-linked=\"Two Harbors raising capital; shares down 3%\" data-tweet=\"$TWO $AMRS - Two Harbors raising capital; shares down 3% https://seekingalpha.com/news/3443814-two-harbors-raising-capital-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3443814-two-harbors-raising-capital-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>47&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443809\" data-ts=\"1552940794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UROV\" target=\"_blank\">UROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443809-urovant-up-1-ahead-of-vibegron-data-readout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urovant up 1% ahead of vibegron data readout</a></h4><ul><li>Urovant Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/UROV' title='Urovant Sciences Ltd.'>UROV</a>) is up <font color=\"green\">1%</font> after hours ahead of tomorrow's <a href=\"https://seekingalpha.com/pr/17447491-urovant-sciences-announce-topline-results-empowur-phase-3-study-vibegron-patients-overactive\" target=\"_blank\">conference call and webcast</a> on topline results from the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03583372?titles=empowur&amp;lead=urovant&amp;rank=1\" target=\"_blank\">EMPOWUR </a>study evaluating vibegron in patients with overactive bladder.</li><li>The event kicks off at 8:30 am ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443809\" data-linked=\"Urovant up 1% ahead of vibegron data readout\" data-tweet=\"$UROV - Urovant up 1% ahead of vibegron data readout https://seekingalpha.com/news/3443809-urovant-up-1-ahead-of-vibegron-data-readout?source=tweet\" data-url=\"https://seekingalpha.com/news/3443809-urovant-up-1-ahead-of-vibegron-data-readout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443805\" data-ts=\"1552940605\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRX\" target=\"_blank\">CPRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443805-catalyst-pharmaceuticals-misses-0_02\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Pharmaceuticals misses by $0.02</a></h4><ul><li>Catalyst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CPRX' title='Catalyst Pharmaceuticals, Inc.'>CPRX</a>): Q4 GAAP EPS of -$0.14 <span style=\"color:red\">misses by $0.02</span>.</li><li>Revenue of $0.5M</li><li>Shares <font color=\"green\">+3.55%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17447564-catalyst-pharmaceuticals-announces-fourth-quarter-year-end-2018-financial-results-provides\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443805\" data-linked=\"Catalyst Pharmaceuticals misses by $0.02\" data-tweet=\"$CPRX - Catalyst Pharmaceuticals misses by $0.02 https://seekingalpha.com/news/3443805-catalyst-pharmaceuticals-misses-0_02?source=tweet\" data-url=\"https://seekingalpha.com/news/3443805-catalyst-pharmaceuticals-misses-0_02\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443800\" data-ts=\"1552940477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443800-tilray-up-5-after-hours-on-q4-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray up 5% after hours on Q4 revenue beat</a></h4><ul><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) <a href=\"https://seekingalpha.com/pr/17447497-tilray-inc-reports-full-year-2018-financial-results\" target=\"_blank\">Q4 result</a>s: Revenue up 204% to $15.5M.</li><li>Net loss: ($31.0M); loss/share: ($0.33).</li><li>Average net selling price per gram: $7.52 (+5%). Total kilogram equivalents sold: 2,053 (+196%).</li><li>Shares are up <font color=\"green\">5% </font>after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443781-tilray-beats-revenue\" target=\"_blank\">Tilray beats on revenue</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443800\" data-linked=\"Tilray up 5% after hours on Q4 revenue beat\" data-tweet=\"$TLRY - Tilray up 5% after hours on Q4 revenue beat https://seekingalpha.com/news/3443800-tilray-up-5-after-hours-on-q4-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3443800-tilray-up-5-after-hours-on-q4-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443796\" data-ts=\"1552940245\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TACO\" target=\"_blank\">TACO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443796-del-tacominus-4-after-light-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Del Taco -4% after light guidance</a></h4><ul><li>Del Taco Restaurants (NASDAQ:<a href='https://seekingalpha.com/symbol/TACO' title='Del Taco Restaurants, Inc.'>TACO</a>) trades lower despite reporting <a href=\"https://seekingalpha.com/news/3443774-del-taco-restaurants-misses-0_01-beats-revenue\" target=\"_blank\">Q4</a> revenue ahead of even the highest analyst estimate.</li><li>System-wide comparable sales were up 1.9% during the quarter, comprised of company-owned restaurant comparable sales growth of +1.0% and franchise comparable sales growth of 3.2%.</li><li>Adjusted EBITDA came in at $23.6M vs. $21.2M consensus.</li><li>Soft guidance may be stealing some glances away from the solid Q4 numbers. Looking ahead, Del Taco expects full-year revenue of $517M to $527M vs. $518M consensus and EPS of $0.47 to $0.52 vs. $0.57.</li><li>TACO <font color=\"red\">-3.59%</font> AH to $10.21.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443774-del-taco-restaurants-misses-0_01-beats-revenue\" target=\"_blank\">Del Taco Restaurants misses by $0.01, beats on revenue</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443796\" data-linked=\"Del Taco -4% after light guidance\" data-tweet=\"$TACO - Del Taco -4% after light guidance https://seekingalpha.com/news/3443796-del-tacominus-4-after-light-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3443796-del-tacominus-4-after-light-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443781\" data-ts=\"1552939840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443781-tilray-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray beats on revenue</a></h4><ul><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>): Q4 GAAP EPS of -$0.33.</li><li>Revenue of $15.53M (+203.9% Y/Y) <font color=\"green\">beats by $1.57M</font>.</li><li>Shares <font color=\"green\">+2.44%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17447497-tilray-inc-reports-full-year-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443781\" data-linked=\"Tilray beats on revenue\" data-tweet=\"$TLRY - Tilray beats on revenue https://seekingalpha.com/news/3443781-tilray-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443781-tilray-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443779\" data-ts=\"1552939764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVAX\" target=\"_blank\">NVAX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443779-novavax-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novavax misses by $0.01, misses on revenue</a></h4><ul><li>Novavax (NASDAQ:<a href='https://seekingalpha.com/symbol/NVAX' title='Novavax, Inc.'>NVAX</a>): Q4 GAAP EPS of -$0.13 <span style=\"color:red\">misses by $0.01</span>.</li><li>Revenue of $6.13M (-41.1% Y/Y) <font color=\"red\">misses by $0.96M</font>.</li><li>Shares <font color=\"green\">+1.25%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17447513-novavax-reports-fourth-quarter-year-end-2018-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443779\" data-linked=\"Novavax misses by $0.01, misses on revenue\" data-tweet=\"$NVAX - Novavax misses by $0.01, misses on revenue https://seekingalpha.com/news/3443779-novavax-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443779-novavax-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443763\" data-ts=\"1552938950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443763-plug-powerplus-9-following-response-to-negative-seeking-alpha-article\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug Power +9% following response to negative Seeking Alpha article</a></h4><ul><li>Plug Power (<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power Inc.'>PLUG</a> <font color='green'>+8.9%</font>) recoups a chunk of Friday's 15% loss prompted by Henrik Alex's <a href=\"https://seekingalpha.com/article/4249063-plug-power-shares-continue-rally-despite-weak-core-business-trends-newly-disclosed-debt\" target=\"_blank\">negative analysis</a> of the company on Seeking Alpha.</li><li>Alex says PLUG's Q4 earnings release included a \"surprise requirement to refinance a large amount  of short-term debt in Q2 2019 without providing much further details\" and says the company \"reverted to upfront revenue recognition for Wal-Mart operating leases in  Q3 2018 which seems to be the main reason behind the company's guidance  increase in mid-October.\"</li><li>In the <a href=\"https://www.plugpower.com/2019/03/response-to-seeking-alpha-article/\" target=\"_blank\">company's response</a>, PLUG says it is \"not sure why the finance obligation is a surprise. We have routinely reported this in current liability as a transparent reflection of what we are doing. The amounts you reference relate specifically to project financings from varied capital leases with balloon obligations; its just how this capital partner structures their deals... Nothing changed, there was no event that accelerated this, nor any of the other suppositions that you were concerned with.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3443763\" data-linked=\"Plug Power +9% following response to negative Seeking Alpha article\" data-tweet=\"$PLUG - Plug Power +9% following response to negative Seeking Alpha article https://seekingalpha.com/news/3443763-plug-powerplus-9-following-response-to-negative-seeking-alpha-article?source=tweet\" data-url=\"https://seekingalpha.com/news/3443763-plug-powerplus-9-following-response-to-negative-seeking-alpha-article\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443753\" data-ts=\"1552936082\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443753-intel-doe-team-for-nations-fastest-computer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel, DOE team for nation&#39;s fastest computer</a></h4><ul><li>Intel (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='red'>-0.4%</font>) <a href=\"https://seekingalpha.com/pr/17447408-u-s-department-energy-intel-deliver-first-exascale-supercomputer\" target=\"_blank\">announces</a> that the company and the U.S. Department of Energy will release the first supercomputer with a performance of one exaFLOP in the US. The \"Aurora\" system is being developed in the DOE's Argonne National Laboratory in Chicago.</li><li>The contract is valued at over $500M and will be delivered to Argonne by Intel and subcontractor Cray (<a href='https://seekingalpha.com/symbol/CRAY' title='Cray Inc.'>CRAY</a> <font color='green'>+2.9%</font>). Delivery is expected by 2021.</li><li>Aurora is purpose-built for traditional high-performance computing and AI. The supercomputer will contain Intel Xᵉ, Intel's future generation Xeon Scalable processor; next-gen Optane DC persistent memory, Cray's Shasta supercomputing system and Slingshot high-performance interconnect, and Intel's One API developer tools for mapping compute engines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443753\" data-linked=\"Intel, DOE team for nation&#39;s fastest computer\" data-tweet=\"$INTC $CRAY - Intel, DOE team for nation&#39;s fastest computer https://seekingalpha.com/news/3443753-intel-doe-team-for-nations-fastest-computer?source=tweet\" data-url=\"https://seekingalpha.com/news/3443753-intel-doe-team-for-nations-fastest-computer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443751\" data-ts=\"1552935492\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAC\" target=\"_blank\">TAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443751-transaltaplus-7-after-activist-investor-group-demands-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransAlta +7% after activist investor group demands change</a></h4><ul><li>TransAlta (<a href='https://seekingalpha.com/symbol/TAC' title='TransAlta Corporation'>TAC</a> <font color='green'>+6.1%</font>) surges to a 52-week high after an investment partnership says it bought 50K shares to take its total ownership to 8.1M shares to <a href=\"https://business.financialpost.com/commodities/energy/transalta-stock-rises-after-u-s-activist-investor-group-demands-change\" target=\"_blank\">take a 10% stake in the company</a> and  will seek board representation.</li><li>Cove Key Bluescape Holdings says it agreed with Bluescape Energy Partners and Mangrove  Partners to use their combined 10% stake to press for changes including operational and cost efficiency, asset optimization, capital allocation and broader strategic initiatives.</li><li>The group says Bluescape executive chairman Charles John Wilder, Jr., and his team  have the experience needed to improve execution and focus at TAC.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443751\" data-linked=\"TransAlta +7% after activist investor group demands change\" data-tweet=\"$TAC - TransAlta +7% after activist investor group demands change https://seekingalpha.com/news/3443751-transaltaplus-7-after-activist-investor-group-demands-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3443751-transaltaplus-7-after-activist-investor-group-demands-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443749\" data-ts=\"1552935309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443749-technology-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers</a></h4><ul><li><strong>Gainers: </strong>Professional Diversity Network (NASDAQ:<a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network, Inc.'>IPDN</a>) <font color=\"green\">+26%</font>. Ideanomics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDEX' title='Ideanomics, Inc.'>IDEX</a>) <font color=\"green\">+17%</font>. DASAN Zhone Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/DZSI' title='DASAN Zhone Solutions, Inc.'>DZSI</a>) <font color=\"green\">+14%</font>. Digital Turbine (NASDAQ:<a href='https://seekingalpha.com/symbol/APPS' title='Digital Turbine, Inc.'>APPS</a>) <font color=\"green\">+10%</font>. Sigma Labs (NASDAQ:<a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a>) <font color=\"green\">+9%</font>.</li> <li><strong>Losers: </strong>NII Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>) <font color=\"red\">-28%</font>. Synaptics Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) <font color=\"red\">-23%</font>. CounterPath Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"red\">-15%</font>. Qutoutiao (NASDAQ:<a href='https://seekingalpha.com/symbol/QTT' title='Qutoutiao Inc.'>QTT</a>) <font color=\"red\">-12%</font>. Ooma (NYSE:<a href='https://seekingalpha.com/symbol/OOMA' title='Ooma, Inc.'>OOMA</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443749\" data-linked=\"Technology - Top 5 Gainers / Losers\" data-tweet=\"$IPDN $IDEX $DZSI - Technology - Top 5 Gainers / Losers https://seekingalpha.com/news/3443749-technology-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443749-technology-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443731\" data-ts=\"1552933287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLNW\" target=\"_blank\">LLNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443731-limelight-genvid-collab-on-streaming-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Limelight, Genvid collab on streaming platform</a></h4><ul><li>Genvid Technologies <a href=\"https://seekingalpha.com/pr/17447276-genvid-technologies-announces-interactive-streaming-r-and-d-collaboration-limelight-networks\" target=\"_blank\">announces</a> a new R&amp;D effort with Limelight Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a>) to help developers and companies to build their own real-time interactive streaming platforms.</li><li>The effort combines Limelight's Realtime Streaming solution and Genvid's interactive capabilities.</li><li>Limelight shares are <font color=\"green\">up 1.2%</font> to $2.94.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443731\" data-linked=\"Limelight, Genvid collab on streaming platform\" data-tweet=\"$LLNW - Limelight, Genvid collab on streaming platform https://seekingalpha.com/news/3443731-limelight-genvid-collab-on-streaming-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3443731-limelight-genvid-collab-on-streaming-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443729\" data-ts=\"1552932979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443729-american-midstream-partners-and-emerge-energy-services-among-energy-materials-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Midstream Partners and Emerge Energy Services among Energy/Materials gainers; FutureFuel and Chaparral Energy among losers</a></h4><ul><li><b>Gainers: </b>American Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a>) <font color=\"green\">+28%</font>. Emerge Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a>) <font color=\"green\">+18%</font>. Smart Sand (NASDAQ:<a href='https://seekingalpha.com/symbol/SND' title='Smart Sand, Inc.'>SND</a>) <font color=\"green\">+11%</font>. VOC Energy Trust (NYSE:<a href='https://seekingalpha.com/symbol/VOC' title='VOC Energy Trust'>VOC</a>) <font color=\"green\">+9%</font>. Nabors Industries (NYSE:<a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>FutureFuel (NYSE:<a href='https://seekingalpha.com/symbol/FF' title='FutureFuel Corp.'>FF</a>) <font color=\"red\">-22%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"red\">-10%</font>. DRDGOLD (NYSE:<a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a>) <font color=\"red\">-9%</font>. Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences, Inc.'>RKDA</a>) <font color=\"red\">-9%</font>. Lilis Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443729\" data-linked=\"American Midstream Partners and Emerge Energy Services among Energy/Materials gainers; FutureFuel and Chaparral Energy among losers\" data-tweet=\"$AMID $EMES $SND - American Midstream Partners and Emerge Energy Services among Energy/Materials gainers; FutureFuel and Chaparral Energy among losers https://seekingalpha.com/news/3443729-american-midstream-partners-and-emerge-energy-services-among-energy-materials-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443729-american-midstream-partners-and-emerge-energy-services-among-energy-materials-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443727\" data-ts=\"1552932679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLIR\" target=\"_blank\">FLIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443727-flirminus-1_3-on-raymond-james-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FLIR -1.3% on Raymond James downgrade</a></h4><ul><li>Raymond James downgrades FLIR Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/FLIR' title='FLIR Systems, Inc.'>FLIR</a>) from Strong Buy to Outperform.</li><li>Last month, FLIR <a href=\"https://seekingalpha.com/news/3432643-flir-reports-mixed-q4-upside-fy-revenue\" target=\"_blank\">reported </a>mixed Q4 results with upside FY guidance.</li><li>Last week, FLIR <a href=\"https://seekingalpha.com/news/3442343-flir-systems-announces-new-d-c-headquarters\" target=\"_blank\">announced</a> a new headquarters for Arlington, Virginia to expand its D.C. presence.</li><li>FLIR shares are <font color=\"red\">down 1.3%</font> to $49.51.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443727\" data-linked=\"FLIR -1.3% on Raymond James downgrade\" data-tweet=\"$FLIR - FLIR -1.3% on Raymond James downgrade https://seekingalpha.com/news/3443727-flirminus-1_3-on-raymond-james-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3443727-flirminus-1_3-on-raymond-james-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443721\" data-ts=\"1552931672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443721-parateck-finance-chief-bids-adieu-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Parateck finance chief bids adieu; shares down 4%</a></h4><ul><li>Paratek Pharmaceuticals (<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color=\"red\">-3.9%</font>) CFO Douglas Pagán will <a href=\"https://seekingalpha.com/pr/17446619-paratek-pharmaceuticals-announces-management-change\" target=\"_blank\">depart </a>on April 5 to join an early-stage biopharma firm. A search for a successor is underway.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443721\" data-linked=\"Parateck finance chief bids adieu; shares down 4%\" data-tweet=\"$PRTK - Parateck finance chief bids adieu; shares down 4% https://seekingalpha.com/news/3443721-parateck-finance-chief-bids-adieu-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3443721-parateck-finance-chief-bids-adieu-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443719\" data-ts=\"1552930929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443719-dar-bio-up-154-on-positive-tamoxifen-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daré Bio up 154% on positive tamoxifen data</a></h4><ul><li>Thinly traded nano cap Daré Bioscience (<a href='https://seekingalpha.com/symbol/DARE' title='Daré Bioscience, Inc.'>DARE</a> <font color=\"green\">+154.3%</font>) is up on a 525x explosion in volume in response to positive <a href=\"https://seekingalpha.com/pr/17446664-dare-bioscience-announces-publication-positive-clinical-findings-vaginal-administration\" target=\"_blank\">clinical data</a> supporting the value proposition of its vaginally administered tamoxifen, DARE-VVA1, for the treatment of vulvar and vaginal atrophy &#40;VVA&#41; in postmenopausal women. The results were just published in <em>Clinical and Experimental Obstetrics and Gynecology</em>.</li><li>Results from four women in the exploratory study who self-administered a tamoxifen-containing suppository every day for a week followed by 2x/week for three months showed significant improvements in vaginal pH and dryness without significant systemic absorption of tamoxifen, an estrogen receptor modulator, a key advantage over oral administration.</li><li>The company says it is preparing clinical trials, adding that if DARE-VVA1 is approved, it will be the first such product for VVA in hormone receptor-positive breast cancer patients.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443719\" data-linked=\"Daré Bio up 154% on positive tamoxifen data\" data-tweet=\"$DARE - Daré Bio up 154% on positive tamoxifen data https://seekingalpha.com/news/3443719-dar-bio-up-154-on-positive-tamoxifen-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3443719-dar-bio-up-154-on-positive-tamoxifen-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443716\" data-ts=\"1552930210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSGN\" target=\"_blank\">MSGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443716-msg-networksplus-5-after-report-of-malone-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MSG Networks +5% after report of Malone interest</a></h4><ul>   <li>MSG Networks (NYSE:<a href='https://seekingalpha.com/symbol/MSGN' title='MSG Networks Inc.'>MSGN</a>) is <font color=\"green\">up 5%</font> today on heavy volume after a weekend report about John Malone's potential <a href=\"https://seekingalpha.com/news/3443448-report-john-malone-eyes-bid-msg-networks\" target=\"_blank\">interest in picking up the regional sports net</a>.</li>    <li>That recoups a couple days' decline in the shares.</li>    <li>It's not the first go-round for a potential sale of MSG Networks, which the Dolan family put up for sale in 2017 before withdrawing it for a lack of suitors.</li>    <li>Malone's bid is said to be contingent on success in his acquiring 21 Fox-owned regional sports nets from Disney -- a bid for which he has enlisted his Atlanta Braves, the Minnesota Twins and the Detroit Pistons.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443716\" data-linked=\"MSG Networks +5% after report of Malone interest\" data-tweet=\"$MSGN - MSG Networks +5% after report of Malone interest https://seekingalpha.com/news/3443716-msg-networksplus-5-after-report-of-malone-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3443716-msg-networksplus-5-after-report-of-malone-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443712\" data-ts=\"1552929509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMT\" target=\"_blank\">AIMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443712-aimmune-down-5-on-fda-timeline-for-ar101\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aimmune down 5% on FDA timeline for AR101</a></h4><ul><li>Aimmune Therapeutics (<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics, Inc.'>AIMT</a> <font color=\"red\">-4.8%</font>) is down on below-average volume in reaction to the FDA's <a href=\"https://seekingalpha.com/pr/17446603-u-s-fda-accepts-bla-filing-aimmune-therapeutics-ar101-peanut-allergy\" target=\"_blank\">review period</a> for AR101 for peanut allergy.</li><li>Despite Breakthrough Therapy and Fast Track status, the agency indicated that it will need a 12-month review period which started in January so the action date will be in January 2020. The standard review period is 10 months which shortens to six months for applications with Priority Review status.</li><li>The company says that it is \"currently engaged in discussions\" with the FDA regarding the timeline, adding that it expects an advisory committee meeting to review the application.</li><li>Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the marketing application.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443712\" data-linked=\"Aimmune down 5% on FDA timeline for AR101\" data-tweet=\"$AIMT - Aimmune down 5% on FDA timeline for AR101 https://seekingalpha.com/news/3443712-aimmune-down-5-on-fda-timeline-for-ar101?source=tweet\" data-url=\"https://seekingalpha.com/news/3443712-aimmune-down-5-on-fda-timeline-for-ar101\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443702\" data-ts=\"1552928361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443702-x-financial-leads-financial-gainers-ppdai-group-and-yintech-investment-holdings-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">X Financial leads financial gainers; PPDAI Group and Yintech Investment Holdings among losers</a></h4><ul><li><b>Gainers:</b> X Financial (NYSE:<a href='https://seekingalpha.com/symbol/XYF' title='X Financial'>XYF</a>) <font color=\"green\">+12%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+11%</font>. Blue Capital Reinsurance Holdings (NYSE:<a href='https://seekingalpha.com/symbol/BCRH' title='Blue Capital Reinsurance Holdings Ltd.'>BCRH</a>) <font color=\"green\">+10%</font>. Triple-S Management (NYSE:<a href='https://seekingalpha.com/symbol/GTS' title='Triple-S Management Corporation'>GTS</a>) <font color=\"green\">+7%</font>. Leju Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> Trinity Place Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/TPHS' title='Trinity Place Holdings Inc.'>TPHS</a>) <font color=\"red\">-14%</font>. PPDAI Group (NYSE:<a href='https://seekingalpha.com/symbol/PPDF' title='PPDAI Group Inc.'>PPDF</a>) <font color=\"red\">-7%</font>. Yintech Investment Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443702\" data-linked=\"X Financial leads financial gainers; PPDAI Group and Yintech Investment Holdings among losers\" data-tweet=\"$XYF $CIFS $BCRH - X Financial leads financial gainers; PPDAI Group and Yintech Investment Holdings among losers https://seekingalpha.com/news/3443702-x-financial-leads-financial-gainers-ppdai-group-and-yintech-investment-holdings-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443702-x-financial-leads-financial-gainers-ppdai-group-and-yintech-investment-holdings-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443701\" data-ts=\"1552928313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPW\" target=\"_blank\">DPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443701-dpw-holdings-sees-crypto-mining-spinoff-q2-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DPW Holdings sees crypto-mining spinoff by Q2-end</a></h4><ul><li>DPW Holdings (<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+21.7%</font>) says it hopes<a href=\"https://seekingalpha.com/pr/17446448-dpw-holdings-inc-provides-update-distribution-shares-digital-farms-inc-stockholders\" target=\"_blank\"> to spin off </a>its Digital Farms crypto-mining subsidiary by the end of Q2 and at the same time it closes on its first data center real-estate partnership.</li><li>It's preparing a Form 10 to be filed with the SEC and expects the final audit of Digital Farms to be completed by the end of April 2019.</li><li>The ratio of Digital Farms shares to be distributed to DPW stockholders may be announced as soon as May 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3438310-dpw-holdings-announces-2_5m-stock-purchase-agreement-ault-and-company-inc\" target=\"_blank\">DPW Holdings announces $2.5M stock purchase agreement with Ault &amp; Company, Inc.</a> (Feb. 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443701\" data-linked=\"DPW Holdings sees crypto-mining spinoff by Q2-end\" data-tweet=\"$DPW - DPW Holdings sees crypto-mining spinoff by Q2-end https://seekingalpha.com/news/3443701-dpw-holdings-sees-crypto-mining-spinoff-q2-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3443701-dpw-holdings-sees-crypto-mining-spinoff-q2-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443700\" data-ts=\"1552928269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRDX\" target=\"_blank\">SRDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443700-surmodics-down-8-on-risk-to-surveil-dcb-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Surmodics down 8% on risk to SurVeil DCB study</a></h4><ul><li>Thinly traded Surmodics (<a href='https://seekingalpha.com/symbol/SRDX' title='Surmodics, Inc.'>SRDX</a> <font color=\"red\">-8.4%</font>) is down on average volume, albeit turnover of only 89K shares, in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/924717/000119312519077492/d700926d8k.htm\" target=\"_blank\">disclosure </a>of an updated FDA advisory on the potential for higher rates of long-term mortality connected to the use of paclitaxel-coated balloons and paclitaxel-eluting stents to treat peripheral artery disease &#40;PAD&#41; in the femoropopliteal artery.</li><li>The company is currently conducting a non-inferiority study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03241459?titles=transcend&amp;lead=surmodics&amp;rank=1\" target=\"_blank\">TRANSCEND</a>, comparing its paclitaxel-coated balloon, SurVeil, compared to Medtronic's (<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a> <font color=\"red\">-1.9%</font>) pacltitaxel-coated device IN.PACT Admiral, in PAD due to stenosis in the femoral and/or popliteal arteries.</li><li>The company says it has reached out to the agency for clarification on how the issue affects ongoing clinical trials.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443700\" data-linked=\"Surmodics down 8% on risk to SurVeil DCB study\" data-tweet=\"$SRDX $MDT - Surmodics down 8% on risk to SurVeil DCB study https://seekingalpha.com/news/3443700-surmodics-down-8-on-risk-to-surveil-dcb-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3443700-surmodics-down-8-on-risk-to-surveil-dcb-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443699\" data-ts=\"1552928213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEOH\" target=\"_blank\">MEOH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443699-top-shareholder-takes-activist-stance-in-dispute-methanex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Top shareholder takes activist stance in dispute with Methanex</a></h4><ul><li>Methanex (<a href='https://seekingalpha.com/symbol/MEOH' title='Methanex Corporation'>MEOH</a> <font color='green'>+1.8%</font>) moves higher after top shareholder M&amp;G Investment Management <a href=\"https://www.ft.com/content/d146b420-498e-11e9-8b7f-d49067e0f50d\" target=\"_blank\">objects to the company's decision</a> to invest heavily in a third methanol production plant in Geismar, La., without the meaningful participation of a strategic partner.</li><li>In what it calls \"an extraordinary action for us,\" M&amp;G sent a <a href=\"https://www.sec.gov/Archives/edgar/data/886977/000091412119000599/mg53473409-ex99_1.htm\" target=\"_blank\">letter to MEOH's board</a> saying the fund manager would nominate alternative directors at the company's next annual meeting.</li><li>\"Engaging in a proxy contest is extraordinary action for us, but in this situation we feel we have no alternative but to do so,\" M&amp;G says in the letter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443699\" data-linked=\"Top shareholder takes activist stance in dispute with Methanex\" data-tweet=\"$MEOH - Top shareholder takes activist stance in dispute with Methanex https://seekingalpha.com/news/3443699-top-shareholder-takes-activist-stance-in-dispute-methanex?source=tweet\" data-url=\"https://seekingalpha.com/news/3443699-top-shareholder-takes-activist-stance-in-dispute-methanex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443697\" data-ts=\"1552927848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLGG\" target=\"_blank\">SLGG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443697-northland-capital-sees-strong-upside-for-super-league-gaming\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northland Capital sees strong upside for Super League Gaming</a></h4><ul> <li>Super League Gaming (<a href='https://seekingalpha.com/symbol/SLGG' title='Super League Gaming, Inc.'>SLGG</a> <font color='green'>+2.5%</font>) gains after Northland Capital Markets initiates coverage with an Outperform rating.</li> <li>The esports company is called a first mover in a potentially massive market.</li> <li>Analyst Michael Latimore observes that organizations such as Topgolf, Samsung or Best Buy can turn their venue into an esports arena and run events anywhere at anytime off the Super League Gaming platform.</li> <li>Lattimore assigns a price target of $15 to SLGG (5X the FY21 revenue estimated discounted back at 25%). Looking at the long term, he see even more upside if SLGG captures \"high-growth SaaS multiples\" of 10X revenue to put the stock at $30.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3443697\" data-linked=\"Northland Capital sees strong upside for Super League Gaming\" data-tweet=\"$SLGG - Northland Capital sees strong upside for Super League Gaming https://seekingalpha.com/news/3443697-northland-capital-sees-strong-upside-for-super-league-gaming?source=tweet\" data-url=\"https://seekingalpha.com/news/3443697-northland-capital-sees-strong-upside-for-super-league-gaming\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443695\" data-ts=\"1552927604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443695-healthcare-names-top-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare names top midday movers</a></h4><ul><li><strong>Gainers: </strong>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+85%</font>. PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+48%</font>. Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"green\">+35%</font>. American Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a>) <font color=\"green\">+28%</font>. Aclaris Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics, Inc.'>ACRS</a>) <font color=\"green\">+21%</font>. Innovate Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INNT' title='Innovate Biopharmaceuticals, Inc.'>INNT</a>) <font color=\"green\">+20%</font>. Professional Diversity Network (NASDAQ:<a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network, Inc.'>IPDN</a>) <font color=\"green\">+20%</font>. Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"green\">+19%</font>. Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"green\">+19%</font>. Tenax Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a>) <font color=\"green\">+15%</font>.</li> <li><strong>Losers: </strong>Aerpio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARPO' title='Aerpio Pharmaceuticals, Inc.'>ARPO</a>) <font color=\"red\">-69%</font>. NII Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>) <font color=\"red\">-29%</font>. FutureFuel (NYSE:<a href='https://seekingalpha.com/symbol/FF' title='FutureFuel Corp.'>FF</a>) <font color=\"red\">-23%</font>. Synaptics Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) <font color=\"red\">-21%</font>. Sensus Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/SRTS' title='Sensus Healthcare, Inc.'>SRTS</a>) <font color=\"red\">-16%</font>. Globus Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>) <font color=\"red\">-16%</font>. GP Strategies (NYSE:<a href='https://seekingalpha.com/symbol/GPX' title='GP Strategies Corporation'>GPX</a>) <font color=\"red\">-15%</font>. Trinity Place Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/TPHS' title='Trinity Place Holdings Inc.'>TPHS</a>) <font color=\"red\">-14%</font>. CounterPath Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"red\">-14%</font>. vTv Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics Inc.'>VTVT</a>) <font color=\"red\">-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443695\" data-linked=\"Healthcare names top midday movers\" data-tweet=\"$DERM $PHAS $ATOS - Healthcare names top midday movers https://seekingalpha.com/news/3443695-healthcare-names-top-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443695-healthcare-names-top-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443692\" data-ts=\"1552926886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443692-geplus-2-barclays-reiterates-overweight-rating-on-2021-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE +2% as Barclays reiterates Overweight rating on 2021 outlook</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a> <font color='green'>+2.1%</font>) is on the move as Barclays analyst Julian Mitchell <a href=\"https://www.barrons.com/articles/ge-stock-continues-to-climb-because-investors-are-focused-on-the-future-51552924612\" target=\"_blank\">reiterates his Overweight rating</a> and $13  price target, saying that even though he lowered his earnings estimates  following last week\u2019s guidance update, he still thinks GE\u2019s industrial business can deliver free cash flow of $6.5B-$7B in 2021 despite projected negative returns this year.</li><li>Mitchell expects GE shares will remain volatile as  investors digest the free cash flow forecast but projections in 2021 for its  industrial unit, do \u201cnot look out of step with the CEO's stated  aspiration for a double-digit FCF margin in the long term, or GE's  history,\u201d and sees GE\u2019s Power business turning from free cash  flow negative to positive by 2021.</li><li>Mitchell is \u201cdismayed\u201d by the extent of the guidance for 2019-20 net losses for GE Capital, which could total more  than $1.5B, but he thinks asset sales will help and that management is taking  seriously a broad range of options to de-risk the business.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443692\" data-linked=\"GE +2% as Barclays reiterates Overweight rating on 2021 outlook\" data-tweet=\"$GE - GE +2% as Barclays reiterates Overweight rating on 2021 outlook https://seekingalpha.com/news/3443692-geplus-2-barclays-reiterates-overweight-rating-on-2021-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3443692-geplus-2-barclays-reiterates-overweight-rating-on-2021-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443681\" data-ts=\"1552924978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSX\" target=\"_blank\">BSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443681-edwards-sapien-3-data-pressures-boston-sci-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edwards&#39; Sapien 3 data pressures Boston Sci, down 5%</a></h4><ul><li>Boston Scientific (<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a> <font color=\"red\">-5.2%</font>) is down on modestly higher volume in apparent response to <a href=\"https://seekingalpha.com/news/3443615-edwards-9-percent-positive-sapien-3-data\" target=\"_blank\">Phase 3 data</a> on Edwards Lifesciences' SAPIEN 3 TAVR device, showing a 1.0% rate of death and disabling stroke at year one in low-risk patients.</li><li>BSX's LOTUS Edge TAVR system showed a 3.6% rate of disabling stroke at year one in a late-stage study (REPRISE III) in high-risk patients (data presented two years ago at EuroPCR). The rate of all-cause mortality was 11.9% compared to 8.5% for SAPIEN 3, albeit in different patient populations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443681\" data-linked=\"Edwards&#39; Sapien 3 data pressures Boston Sci, down 5%\" data-tweet=\"$BSX - Edwards&#39; Sapien 3 data pressures Boston Sci, down 5% https://seekingalpha.com/news/3443681-edwards-sapien-3-data-pressures-boston-sci-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3443681-edwards-sapien-3-data-pressures-boston-sci-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443680\" data-ts=\"1552924936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443680-iconix-brand-group-leads-consumer-gainers-nu-skin-enterprises-and-orchids-paper-products\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Iconix Brand Group leads consumer gainers; Nu Skin Enterprises and Orchids Paper Products among losers</a></h4><ul><li><b>Gainers: </b>Iconix Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a>) <font color=\"green\">+16%</font>. Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+11%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+8%</font>. Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi, Inc.'>FAMI</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Celsius Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CELH' title='Celsius Holdings, Inc.'>CELH</a>) <font color=\"red\">-8%</font>. Orchids Paper Products (NYSEMKT:<a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a>) <font color=\"red\">-8%</font>. Pingtan Marine Enterprise (NASDAQ:<a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a>) <font color=\"red\">-7%</font>. Nu Skin Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/NUS' title='Nu Skin Enterprises, Inc.'>NUS</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443680\" data-linked=\"Iconix Brand Group leads consumer gainers; Nu Skin Enterprises and Orchids Paper Products among losers\" data-tweet=\"$ICON $VFF $NBEV - Iconix Brand Group leads consumer gainers; Nu Skin Enterprises and Orchids Paper Products among losers https://seekingalpha.com/news/3443680-iconix-brand-group-leads-consumer-gainers-nu-skin-enterprises-and-orchids-paper-products?source=tweet\" data-url=\"https://seekingalpha.com/news/3443680-iconix-brand-group-leads-consumer-gainers-nu-skin-enterprises-and-orchids-paper-products\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443672\" data-ts=\"1552923641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443672-cellcom-israel-down-3-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom Israel down 3% post Q4 results</a></h4><ul><li>Cellcom Israel (<a href='https://seekingalpha.com/symbol/CEL' title='Cellcom Israel Ltd.'>CEL</a> <font color=\"red\">-3.8%</font>) reported Q4 revenue decrease of 5.8% Y/Y to NIS 918M, attributed to a 4.9% decrease in service revenues and an 8.4% decrease in equipment revenues.</li><li>Cellular Segment: Service revenue NIS 416M (-7.8% Y/Y); and Equipment revenue NIS 159M (-22.1% Y/Y).</li><li>Fixed-line segments: Service revenue NIS 301M (-0.7% Y/Y); and Equipment revenue NIS 82M (+39% Y/Y).</li><li>Q4 Gross margin <font color=\"red\">declined by 390 bps</font> to 26.4%; and operating margin <font color=\"red\">declined by 375 bps</font> to 0.87%.</li><li>SG&amp;A expenses were NIS 234M (-6% Y/Y), declined ws due to decrease in salaries expenses and doubtful accounts expenses.</li><li>Free cash flow for the quarter was NIS 7M (-90.9% Y/Y), reflecting a decrease in receipts from customers as a result of decrease in the Company's revenues and higher cash capital expenditures in fixed assets.</li><li>Adj. EBITDA was NIS 163M (-13.8% Y/Y) and as percentage of revenue <font color=\"red\">declined by 163 bps</font> to 17.8%.</li><li>Segment Adj. EBITDA margins: Cellular 16.9% <font color=\"red\">down by 110 bps</font>; and Fixed-line 17.2% <font color=\"red\">down by 240 bps</font>.</li><li>Cellular Performance Indicators: FY18 Cellular subscribers 2,851 (+1.2% Y/Y); Churn Rate for Q4 11.1%; and Q4 Monthly cellular ARPU NIS 49 (-8.6% Y/Y).</li><li>Fixed-line Performance Indicators: FY18 Internet infrastructure field subscribers 269k (+21.2% Y/Y); and TV field subscribers 219k (+28.8% Y/Y).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443489-cellcom-israel-reports-q4-results\" target=\"_blank\">Cellcom Israel reports Q4 results</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443672\" data-linked=\"Cellcom Israel down 3% post Q4 results\" data-tweet=\"$CEL - Cellcom Israel down 3% post Q4 results https://seekingalpha.com/news/3443672-cellcom-israel-down-3-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443672-cellcom-israel-down-3-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443666\" data-ts=\"1552922344\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INNT\" target=\"_blank\">INNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443666-innovate-bio-up-19-in-capital-raise-to-fund-late-stage-innminus-202-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovate Bio up 19% in capital raise to fund late-stage INN-202 study</a></h4><ul><li>Thinly traded nano cap Innovate Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/INNT' title='Innovate Biopharmaceuticals, Inc.'>INNT</a> <font color=\"green\">+18.7%</font>) is up on a 13x surge in volume following its <a href=\"https://seekingalpha.com/pr/17446885-innovate-biopharmaceuticals-announces-entry-securities-purchase-agreement-fund-initiation\" target=\"_blank\">announcement </a>of a capital raise that will fund its first Phase 3 clinical trial evaluating lead candidate INN-202 in celiac disease.</li><li>The company has agreed to sell up to ~4.3M common shares to SDS Capital Partners II LLC and certain other investors at $2.33 per share plus up to ~4.3M one-year warrants and up to ~2.6M five-year warrants. The former will be exercisable at $4.00 per common share and the latter at a volume-weighted average price over a certain period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443666\" data-linked=\"Innovate Bio up 19% in capital raise to fund late-stage INN-202 study\" data-tweet=\"$INNT - Innovate Bio up 19% in capital raise to fund late-stage INN-202 study https://seekingalpha.com/news/3443666-innovate-bio-up-19-in-capital-raise-to-fund-late-stage-innminus-202-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3443666-innovate-bio-up-19-in-capital-raise-to-fund-late-stage-innminus-202-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443664\" data-ts=\"1552922064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEV\" target=\"_blank\">ABEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443664-ambev-rallies-after-strong-carnival-data-read\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambev rallies after strong Carnival data read</a></h4><ul> <li>Shares of Ambev (<a href='https://seekingalpha.com/symbol/ABEV' title='Ambev S.A.'>ABEV</a> <font color='green'>+4.2%</font>) break higher after beer sales data in Brazil shows strong demand during the Carnival holiday period last month.</li> <li>Tracking from two different sources indicates that beer volume was at or slightly above the forecast for 5% year-over-year growth, according to Bloomberg.</li> <li>Ambev is up 15% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443664\" data-linked=\"Ambev rallies after strong Carnival data read\" data-tweet=\"$ABEV - Ambev rallies after strong Carnival data read https://seekingalpha.com/news/3443664-ambev-rallies-after-strong-carnival-data-read?source=tweet\" data-url=\"https://seekingalpha.com/news/3443664-ambev-rallies-after-strong-carnival-data-read\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443661\" data-ts=\"1552921549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRS\" target=\"_blank\">ACRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443661-aclaris-up-22-after-q4-report-business-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aclaris up 22% after Q4 report/business update</a></h4><ul><li>Aclaris Therapeutics (<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics, Inc.'>ACRS</a> <font color=\"green\">+22.4%</font>) is up on almost 30% higher volume following its <a href=\"https://seekingalpha.com/pr/17446520-aclaris-therapeutics-reports-fourth-quarter-full-year-2018-financial-results-provides-update\" target=\"_blank\">Q4 report</a> and 2019 outlook. Highlights:</li><li>Total revenues: $3.7M (+267%); net loss: ($38.6M) (-68.6%).</li><li><strong>Pipeline update</strong>:</li><li>Topline data from two Phase 3 clinical trials, THWART-1 and THWART-2, evaluating A-101 for the treatment of common warts should be available in H2. If positive, including results from an open-label safety study, the company will file a U.S. marketing application in H1 2020.</li><li>ATI-502: Topline data from a Phase 2 study, AA-201 Topical, in alopecia areata &#40;AA&#41; should be available next quarter. Six-month data from another Phase 2, AGA-201 Topical, in androgenic alopecia should be available next quarter. Six-month data from yet another Phase 2, VITI-201 Topical, in vitiligo patients should also be available next quarter. Topline data from an open-label Phase 2, AD-201 Topical, in atopic dermatitis should be available mid-year.</li><li>ATI-501: Topline data from an AA study should be available in H2.</li><li>ATI-450: IND to be filed mid-year for rheumatoid arthritis. Clinical trials should launch in H2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443661\" data-linked=\"Aclaris up 22% after Q4 report/business update\" data-tweet=\"$ACRS - Aclaris up 22% after Q4 report/business update https://seekingalpha.com/news/3443661-aclaris-up-22-after-q4-report-business-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3443661-aclaris-up-22-after-q4-report-business-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443660\" data-ts=\"1552921373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NYT\" target=\"_blank\">NYT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443660-cannonball-upgrades-nyt-to-buy-sees-18-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cannonball upgrades NYT to Buy, sees 18% upside</a></h4><ul>   <li>Cannonball Research sees 18% upside in the New York Times Co. (<a href=\"http://seekingalpha.com/symbol/NYT\" target=\"_blank\">NYT</a> <font color=\"green\">+1.5%</font>) in a new note.</li>    <li>The firm upgraded its recommendation to Buy from Neutral and departed from the average price target, boosting its expectations to $41/share from $29/share.</li>    <li>Share have been on a roll since a three-month low on Jan. 3, <font color=\"green\">up 62.5%</font> since then.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443660\" data-linked=\"Cannonball upgrades NYT to Buy, sees 18% upside\" data-tweet=\"$NYT - Cannonball upgrades NYT to Buy, sees 18% upside https://seekingalpha.com/news/3443660-cannonball-upgrades-nyt-to-buy-sees-18-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3443660-cannonball-upgrades-nyt-to-buy-sees-18-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443659\" data-ts=\"1552921329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443659-dermira-leads-healthcare-gainers-tenax-therapeutics-and-cohbar-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dermira leads healthcare gainers; Tenax Therapeutics and CohBar among the losers</a></h4><ul><li><b>Gainers: </b>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+100%</font>. PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+67%</font>. Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"green\">+34%</font>. Innovate Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INNT' title='Innovate Biopharmaceuticals, Inc.'>INNT</a>) <font color=\"green\">+33%</font>. Aclaris Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRS' title='Aclaris Therapeutics, Inc.'>ACRS</a>) <font color=\"green\">+23%</font>.</li><li><b>Losers: </b>Aerpio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARPO' title='Aerpio Pharmaceuticals, Inc.'>ARPO</a>) <font color=\"red\">-69%</font>. Sensus Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/SRTS' title='Sensus Healthcare, Inc.'>SRTS</a>) <font color=\"red\">-16%</font>. vTv Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics Inc.'>VTVT</a>) <font color=\"red\">-14%</font>. CohBar (NASDAQ:<a href='https://seekingalpha.com/symbol/CWBR' title='CohBar, Inc.'>CWBR</a>) <font color=\"red\">-12%</font>. Tenax Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TENX' title='Tenax Therapeutics, Inc.'>TENX</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443659\" data-linked=\"Dermira leads healthcare gainers; Tenax Therapeutics and CohBar among the losers\" data-tweet=\"$DERM $PHAS $ATOS - Dermira leads healthcare gainers; Tenax Therapeutics and CohBar among the losers https://seekingalpha.com/news/3443659-dermira-leads-healthcare-gainers-tenax-therapeutics-and-cohbar-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443659-dermira-leads-healthcare-gainers-tenax-therapeutics-and-cohbar-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443655\" data-ts=\"1552921249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YIN\" target=\"_blank\">YIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443655-yintechminus-4_4-after-q4-impairment-charge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yintech -4.4% after Q4 impairment charge</a></h4><ul><li>Yintech Investment (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>)<font color=\"red\"> falls 4.4%</font> after recording <a href=\"https://seekingalpha.com/pr/17446451-yintech-reports-fourth-quarter-full-year-2018-unaudited-financial-results\" target=\"_blank\">non-cash impairment charges</a> of RMB 639.0M ($95.2M) on its Gold Master unit acquired in 2016.</li><li>Q4 net loss was RMB 746.1M ($108.5M) vs. a loss of RMB 63.6M in the year-ago quarter and RMB 33.9M in Q3.</li><li>Excluding the impairment charges, Q4 net adjusted loss was RMB 140.6M.</li><li>Sees Q1 revenue from commissions, interest income, and other revenue of RMB 220M-RMB 240M and sees Q1 revenue from trading gains of RMB 110M-RMB 130M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443511-yintech-investment-reports-q4-results\" target=\"_blank\">Yintech Investment reports Q4 results</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443655\" data-linked=\"Yintech -4.4% after Q4 impairment charge\" data-tweet=\"$YIN - Yintech -4.4% after Q4 impairment charge https://seekingalpha.com/news/3443655-yintechminus-4_4-after-q4-impairment-charge?source=tweet\" data-url=\"https://seekingalpha.com/news/3443655-yintechminus-4_4-after-q4-impairment-charge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443641\" data-ts=\"1552919861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HZN\" target=\"_blank\">HZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443641-on-horizon-globals-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Horizon Global&#39;s Q4 results</a></h4><ul><li>Horizon Global (<a href='https://seekingalpha.com/symbol/HZN' title='Horizon Global Corporation'>HZN</a> <font color=\"red\">-0.8%</font>) reported Q4 revenue of $171.96M a decrease of 12.3% Y/Y, and -10% Y/Y on constant currency basis.</li><li>Segment sales: Americas $70.88M (-19.7% Y/Y); Europe-Africa $66.84M (-8.3% Y/Y); and Asia-Pacific $34.24M (-1.6% Y/Y).</li><li>Q4 Gross margin <font color=\"red\">declined by 1,015 bps</font> to 8.3%.</li><li>Operating loss was $29.04M, compared to $2.11M a year ago; and Adj. operating loss of $15.77M.</li><li>Net cash used for operating activities YTD were $70.5M, compared to cash provided $14.16M a year ago.</li><li>Company Completed second lien term loan agreement to provide additional liquidity to support 2019 business plan.</li><li>Company announced appointment of Barry Steele as permanent Chief Financial Officer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443502-horizon-global-misses-0_69-revenue-line\" target=\"_blank\">Horizon Global misses by $0.69,  revenue in-line</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443641\" data-linked=\"More on Horizon Global&#39;s Q4 results\" data-tweet=\"$HZN - More on Horizon Global&#39;s Q4 results https://seekingalpha.com/news/3443641-on-horizon-globals-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443641-on-horizon-globals-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443640\" data-ts=\"1552919684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443640-investors-mull-caesars-eldorado-combination\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors mull Caesars-Eldorado combination</a></h4><ul> <li>Caesars Entertainment (<a href='https://seekingalpha.com/symbol/CZR' title='Caesars Entertainment Corporation'>CZR</a> <font color='green'>+2.8%</font>) and Eldorado Resorts (<a href='https://seekingalpha.com/symbol/ERI' title='Eldorado Resorts, Inc.'>ERI</a> <font color='red'>-1.6%</font>) trade in different directions after Reuters reported on merger talks between the two casino companies.</li><li>Analysts have speculated on a Caesars-Eldorado combination in the past due to their complementary casino portfolios. Eldorado owns and operates 26 properties across 12 U.S. states, while Caesars is one of the two dominant players on the Las Vegas Strip.</li>  <li>Macquarie thinks Eldorado would pay up to $10 to $14 per Caesars share if the companies combine, per Bloomberg.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443478-eldorado-resorts-caesars-explore-merger\" target=\"_blank\">Eldorado Resorts, Caesars explore merger</a> (March 18)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443640\" data-linked=\"Investors mull Caesars-Eldorado combination\" data-tweet=\"$CZR $ERI - Investors mull Caesars-Eldorado combination https://seekingalpha.com/news/3443640-investors-mull-caesars-eldorado-combination?source=tweet\" data-url=\"https://seekingalpha.com/news/3443640-investors-mull-caesars-eldorado-combination\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443634\" data-ts=\"1552919545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABT\" target=\"_blank\">ABT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443634-abbotts-next-gen-lvad-shows-treatment-benefit-in-comparative-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abbott&#39;s next-gen LVAD shows treatment benefit in comparative study</a></h4><ul><li>Results from a clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02224755?titles=momentum+3&amp;lead=abbott&amp;rank=2\" target=\"_blank\">MOMENTUM 3</a>, comparing Abbott's (<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color=\"red\">-2.2%</font>) HeartMate 3 left ventricular assist device &#40;LVAD&#41; to the HeartMate II in patients living with advanced heart failure, showed a 79% survival rate at year two compared to 76.7% for the HeartMate II. The data were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans.</li><li>Patients receiving the HeartMate 3 reported a 30-point improvement in Quality of Life scores. They were able to walk almost 200 yards further in six minutes compared to pre-implant baseline.</li><li>The rate of thrombosis (clotting) at year two was 1.4% in the HeartMate 3 cohort versus 13.9% for HeartMate II.</li><li>The FDA <a href=\"https://seekingalpha.com/news/3398890-fda-oks-abbotts-heartmate-3-lvad\" target=\"_blank\">approved</a> HeartMate 3 in October 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443634\" data-linked=\"Abbott&#39;s next-gen LVAD shows treatment benefit in comparative study\" data-tweet=\"$ABT - Abbott&#39;s next-gen LVAD shows treatment benefit in comparative study https://seekingalpha.com/news/3443634-abbotts-next-gen-lvad-shows-treatment-benefit-in-comparative-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3443634-abbotts-next-gen-lvad-shows-treatment-benefit-in-comparative-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443635\" data-ts=\"1552919328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443635-rio-tinto-rejects-bid-to-reveal-emission-targets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto rejects bid to reveal emission targets</a></h4><ul><li>Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto Group'>RIO</a> <font color='green'>+2.1%</font>) says it will <a href=\"http://www.mining.com/rio-tinto-rejects-push-activist-shareholders-reveal-emission-targets/\" target=\"_blank\">recommend shareholders vote against</a> a resolution requiring it to report its direct emissions and those of its customers in greater detail.</li><li>Rio says it does not support the proposal by activist shareholders because the company is not in control of emissions released by its customers.</li><li>The proposed rule change would have Rio enact transition plans to meet the Paris Climate Agreement\u2019s goal of limiting global warming to 1.5 degrees Celsius (2.7 Fahrenheit).</li><li>The plans would include short-, medium- and long-term targets to reduce scope 1, 2 and 3 greenhouse gas emissions and detailed strategies to meet targets in each annual report starting from 2020; Rio says scope 3 emissions are from its customers, mainly steelmakers in China.</li><li>\"Options exist for the reduction of these emissions, but the speed,  economic viability and ultimate deployment of these technologies lie  within the control of our customers, not Rio Tinto,\" Rio says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443635\" data-linked=\"Rio Tinto rejects bid to reveal emission targets\" data-tweet=\"$RIO - Rio Tinto rejects bid to reveal emission targets https://seekingalpha.com/news/3443635-rio-tinto-rejects-bid-to-reveal-emission-targets?source=tweet\" data-url=\"https://seekingalpha.com/news/3443635-rio-tinto-rejects-bid-to-reveal-emission-targets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443631\" data-ts=\"1552919168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSTR\" target=\"_blank\">FSTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443631-on-l-b-foster-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on L.B. Foster Q4 results</a></h4><ul><li>L.B. Foster (<a href='https://seekingalpha.com/symbol/FSTR' title='L.B. Foster Company'>FSTR</a> <font color=\"red\">-2.3%</font>) reports <a href=\"https://seekingalpha.com/pr/17446587-l-b-foster-reports-fourth-quarter-full-year-2018-operating-results\" target=\"_blank\">Q4</a> revenue growth by 16.4% Y/Y to $164.5M.</li><li>Rail Products and Services sales increased by 18.7% Y/Y, Construction Products sales increased by 15.3% Y/Y and Tubular and Energy Services sales increased by 13.1% Y/Y.</li><li>Gross margin <font color=\"red\">declined 136 bps</font> to 18.6% and Adj. EBITDA <font color=\"red\">declined 57 bps</font> to 6.9%.</li><li>New orders were $138.7M (+20.2% Y/Y), due to 42.2% and 29.4% increases in Rail and Tubular, respectively which was partially offset by a 23.4% reduction in Construction.</li><li>Backlog increased by 32.1% Y/Y to $220.4M.</li><li>Net cash provided by operating activities for 2018 totaled $26M.</li><li>There was a reduction in outstanding debt of $55M, or a 42.3% decline Y/Y.</li><li>The company results also include $43.4M expense recognized as a result of the settlement of the concrete tie warranty claim with Union Pacific Railroad.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443536-l-b-foster-misses-0_26-misses-revenue\" target=\"_blank\">L.B. Foster misses by $0.26, misses on revenue</a> (Mar. 18 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443631\" data-linked=\"More on L.B. Foster Q4 results\" data-tweet=\"$FSTR - More on L.B. Foster Q4 results https://seekingalpha.com/news/3443631-on-l-b-foster-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443631-on-l-b-foster-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443629\" data-ts=\"1552917947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRN\" target=\"_blank\">CTRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443629-macellum-turns-up-heat-on-citi-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macellum turns up the heat on Citi Trends</a></h4><ul><li>Macellum nominates four candidates for the board at Citi Trends (<a href='https://seekingalpha.com/symbol/CTRN' title='Citi Trends, Inc.'>CTRN</a> <font color='green'>+5.5%</font>). The activist firm's nominees are Theresa Backes, Paul Metcalf, Peter Sachse and Kenneth Seipel.</li><li>Macellum say it's \"deeply concerned\" by the board's lack of urgency in addressing many of the issues facing the company.</li> <li>Macellum on CTRN's performance: \"Over a one-year period, Citi Trends' stock has delivered a negative 27% return to stockholders.  This represents an underperformance to the S&amp;P 500 Retailing Index by 28%, the S&amp;P 500 Index by 35%, the Russell 2000 Index by 26% and off-price peers (BURL, ROST, and TJX) by 46%.\"</li><li>\"Citi Trends continues to experience poor operating performance.  Worst yet, the operating declines appear to be accelerating.\"</li><li>Macellum holds a 3.8% stake in Citi Trends.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17446491-macellum-advisors-nominates-four-highly-qualified-directors-election-citi-trends-inc-s-2019\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443629\" data-linked=\"Macellum turns up the heat on Citi Trends\" data-tweet=\"$CTRN - Macellum turns up the heat on Citi Trends https://seekingalpha.com/news/3443629-macellum-turns-up-heat-on-citi-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3443629-macellum-turns-up-heat-on-citi-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443626\" data-ts=\"1552917946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTE\" target=\"_blank\">PTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443626-polarityte-down-13-on-sec-investigation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PolarityTE down 13% on SEC investigation</a></h4><ul><li>Thinly traded micro cap PolarityTE (<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a> <font color=\"red\">-13.4%</font>) slumps on almost 25% higher volume in apparent response to its disclosure that, on March 4, it received a formal order of investigation from the SEC concerning possible violations of federal securities laws (<a href=\"https://www.sec.gov/Archives/edgar/data/1076682/000149315219003515/form10-kt.htm#a_005\" target=\"_blank\">2018 annual report</a>, page 48).</li><li>On September 7, 2018, the SEC filed a complaint in a New York court accusing former CFO and CIO Barry Honig, the owner of 5% of PolarityTE, of manipulating the price of three public companies (not including PolarityTE), amended on March 8.</li><li>PolarityTE received an SEC subpoena on March 1 requesting additional documents related to communications between the company and others, including Mr. Honig, Johns Stetson and Michael Brauser, the Majesco transaction, its current regenerative medicine business, including SkinTE, and any promotion of the company or its securities.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3388837-sec-charges-frost-honig-stock-promotion-schemes-opko-18-percent\" target=\"_blank\">SEC charges Frost and Honig with stock promotion schemes; OPKO down 18%</a> (Sept. 7, 2018)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443626\" data-linked=\"PolarityTE down 13% on SEC investigation\" data-tweet=\"$PTE - PolarityTE down 13% on SEC investigation https://seekingalpha.com/news/3443626-polarityte-down-13-on-sec-investigation?source=tweet\" data-url=\"https://seekingalpha.com/news/3443626-polarityte-down-13-on-sec-investigation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443627\" data-ts=\"1552917871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WP\" target=\"_blank\">WP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443627-worldpayplus-11-after-fis-deal-represents-14-premium\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Worldpay +11% after FIS deal represents 14% premium</a></h4><ul><li>Worldpay (NYSE:<a href='https://seekingalpha.com/symbol/WP' title='Worldpay, Inc.'>WP</a>)<font color=\"green\"> surges 11%</font> after FIS (<a href='https://seekingalpha.com/symbol/FIS' title='Fidelity National Information Services, Inc.'>FIS</a> <font color='red'>-0.2%</font>) agrees to the payments company in a deal that places an almost 14% premium on Worldpay shares based on March 15 closing prices.</li><li>FIS agrees to pay 0.9287 FIS shares plus $11.00 in cash for each share of Worldpay, equivalent to ~$112.12 per share based on FIS's close on March 15.</li><li>FIS sees $500M of revenue synergies and $400M of run-rate expense synergies and almost $4.5B of free cash flow in three years.</li><li>Sees refinancing Worldpay debt.</li><li>FIS accelerates organic revenue growth outlook to 6%-9% through 2021.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443480-fidelity-national-scoops-worldpay-35b\" target=\"_blank\">Fidelity National scoops up Worldpay for $35B</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443627\" data-linked=\"Worldpay +11% after FIS deal represents 14% premium\" data-tweet=\"$WP $FIS - Worldpay +11% after FIS deal represents 14% premium https://seekingalpha.com/news/3443627-worldpayplus-11-after-fis-deal-represents-14-premium?source=tweet\" data-url=\"https://seekingalpha.com/news/3443627-worldpayplus-11-after-fis-deal-represents-14-premium\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443619\" data-ts=\"1552917216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPX\" target=\"_blank\">GPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443619-gp-strategies-slides-13_5-due-to-weak-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GP Strategies slides 13.5% due to weak margins</a></h4><ul><li>GP Strategies (<a href='https://seekingalpha.com/symbol/GPX' title='GP Strategies Corporation'>GPX</a> <font color=\"red\">-13.5%</font>) reports <a href=\"https://seekingalpha.com/pr/17446452-gp-strategies-reports-fourth-quarter-2018-financial-results-positive-outlook-2019\" target=\"_blank\">Q4</a> revenue growth by 1% Y/Y to $132.8M.</li><li>Overall Q4 margins: Gross <font color=\"red\">declined 266 bps</font> to 13.8%; Operating <font color=\"red\">declined 33 bps</font> to 2% and Adj. EBITDA also <font color=\"red\">declined 364 bps</font> to 5.64%.</li><li>Significantly a record level increase of 22% Y/Y in backlog of $327.4M.</li><li>The company completed TTi Global acquisition, significantly enhancing GP Strategies' service offerings and customer base in the automotive industry.</li><li>Cash provided by operating activities of $7.7M (+51% Y/Y) &amp; cash of $13.4M (-43.2% Y/Y).</li><li>Repurchased ~ 0.35M shares of its common stock in the open market for a total cost of ~$8M.</li><li>\"We anticipate achieving both significant revenue and EBITDA increases in 2019. While our 2018 results were disappointing, we have made substantial progress in our long term strategic objectives.\" stated Scott N. Greenberg, CEO of GP Strategies.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443505-gp-strategies-misses-0_21-misses-revenue\" target=\"_blank\">GP Strategies misses by $0.21, misses on revenue</a> (Mar. 18 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443619\" data-linked=\"GP Strategies slides 13.5% due to weak margins\" data-tweet=\"$GPX - GP Strategies slides 13.5% due to weak margins https://seekingalpha.com/news/3443619-gp-strategies-slides-13_5-due-to-weak-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3443619-gp-strategies-slides-13_5-due-to-weak-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443615\" data-ts=\"1552916675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EW\" target=\"_blank\">EW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443615-edwards-up-9-on-positive-sapien-3-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edwards up 9% on positive Sapien 3 data</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17446242-edwards-sapien-3-valve-proves-superior-surgery-partner-3-trial\" target=\"_blank\">Results </a>from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03193801?titles=partner&amp;lead=edwards+lifesciences&amp;rank=3\" target=\"_blank\">PARTNER 3</a>, evaluating Edwards Lifesciences' (<a href='https://seekingalpha.com/symbol/EW' title='Edwards Lifesciences Corporation'>EW</a> <font color=\"green\">+9.1%</font>) SAPIEN 3 mitral valve in patients with severe symptomatic aortic stenosis (narrowing of the aorta) showed its superiority to surgery. The data were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans.</li><li>Patients receiving transcatheter aortic valve replacement &#40;TAVR&#41; with the SAPIEN 3 experienced a 46% lower event rate (all-cause mortality, stroke, rehospitalization at year one) compared to open-heart surgery. Specifically, the event rate at year one was 8.5% in the SAPIEN 3 group compared to 15.1% for the surgery group. In addition, the rate of death and disabling stroke at year one in the SAPIEN 3 group was 1.0% compared to 2.9% for the surgery group.</li><li>Leerink appears unimpressed, predicting that shares will fade since there will be no \"new meaningful data\" or \"indication expansions\" for TAVR over the next two years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443615\" data-linked=\"Edwards up 9% on positive Sapien 3 data\" data-tweet=\"$EW - Edwards up 9% on positive Sapien 3 data https://seekingalpha.com/news/3443615-edwards-up-9-on-positive-sapien-3-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3443615-edwards-up-9-on-positive-sapien-3-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443609\" data-ts=\"1552915553\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443609-riot-pxlw-and-atos-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RIOT, PXLW and ATOS among premarket gainers</a></h4><ul><li>PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+108%</font> on positive PB2452 <a href=\"https://seekingalpha.com/news/3443559-phasebio-102-percent-premarket-positive-pb2452-data\" target=\"_blank\">data</a>.</li><li>Dermira (NASDAQ:<a href='https://seekingalpha.com/symbol/DERM' title='Dermira, Inc.'>DERM</a>) <font color=\"green\">+82%</font> on positive lebrikizumab <a href=\"https://seekingalpha.com/news/3443541-dermira-74-percent-premarket-positive-lebrikizumab-data\" target=\"_blank\">data</a>.</li><li>Leap Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/LPTX' title='Leap Therapeutics, Inc.'>LPTX</a>) <font color=\"green\">+31%</font> on positive DKN-01 <a href=\"https://seekingalpha.com/news/3443530-leap-52-percent-premarket-positive-dknminus-01-data\" target=\"_blank\">data</a>.</li><li>American Midstream Partners, LP (NYSE:<a href='https://seekingalpha.com/symbol/AMID' title='American Midstream Partners, LP'>AMID</a>) <font color=\"green\">+30%</font> on <a href=\"https://seekingalpha.com/news/3443522-american-midstream-taken-private-arclight-energy-5_25-unit\" target=\"_blank\">being taken private</a> by ArcLight Energy for $5.25/unit.</li><li>Hancock Jaffe Laboratories (NASDAQ:<a href='https://seekingalpha.com/symbol/HJLI' title='Hancock Jaffe Laboratories, Inc.'>HJLI</a>) <font color=\"green\">+20%</font> on <a href=\"https://seekingalpha.com/pr/17446839-hancock-jaffe-announces-successful-start-coreograft-study-texas-heart-institute\" target=\"_blank\">successful start</a> of its CoreoGraftÒ pre-clinical feasibility study at the Texas Heart Institute.</li><li>Pixelworks (NASDAQ:<a href='https://seekingalpha.com/symbol/PXLW' title='Pixelworks, Inc.'>PXLW</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/pr/17446972-black-shark-2-smartphone-takes-gaming-visual-performance-next-level-pixelworks-display\" target=\"_blank\">improved</a> gaming visual performance with Pixelworks Display Technology.</li><li>Worldpay (NYSE:<a href='https://seekingalpha.com/symbol/WP' title='Worldpay, Inc.'>WP</a>) <font color=\"green\">+13%</font> as Fidelity National <a href=\"https://seekingalpha.com/news/3443480-fidelity-national-scoops-worldpay-35b\" target=\"_blank\">scoops</a> up Worldpay for $35B.</li><li>Atossa Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOS' title='Atossa Genetics Inc.'>ATOS</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/pr/17446816-atossa-genetics-announces-receipt-10-million\" target=\"_blank\">receipt</a> of $10 million from exercises of previously outstanding warrants.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+11%</font>.</li><li>Catabasis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals, Inc.'>CATB</a>) <font color=\"green\">+7%</font>.</li><li>Akari Therapeutics Plc (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"green\">+6%</font>.</li><li>DropCar (NASDAQ:<a href='https://seekingalpha.com/symbol/DCAR' title='DropCar, Inc.'>DCAR</a>) <font color=\"green\">+6%</font>.</li><li>China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443609\" data-linked=\"RIOT, PXLW and ATOS among premarket gainers\" data-tweet=\"$PHAS $DERM $LPTX - RIOT, PXLW and ATOS among premarket gainers https://seekingalpha.com/news/3443609-riot-pxlw-and-atos-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443609-riot-pxlw-and-atos-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443608\" data-ts=\"1552915493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443608-amarin-up-2-on-new-reduce-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin up 2% on new REDUCE -IT data</a></h4><ul><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) is up <font color=\"green\">2%</font> premarket on modest volume on the heels of <a href=\"https://seekingalpha.com/pr/17446931-vascepa-icosapent-ethyl-showed-30-percent-reduction-total-cardiovascular-events-including\" target=\"_blank\">new data</a> from the large-scale REDUCE-IT study of Vascepa (icosapent ethyl). The results were presented at the American College of Cardiology Annual Scientific Sessions in New Orleans.</li><li>Patients receiving Vascepa experienced 30% less cardiovascular events compared to placebo.</li><li>The company will webcast a physician panel discussion for investors and analysts today at 5:00 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443608\" data-linked=\"Amarin up 2% on new REDUCE -IT data\" data-tweet=\"$AMRN - Amarin up 2% on new REDUCE -IT data https://seekingalpha.com/news/3443608-amarin-up-2-on-new-reduce-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3443608-amarin-up-2-on-new-reduce-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443604\" data-ts=\"1552915401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443604-nii-selling-nextel-brazil-to-america-movil-to-wind-up-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NII selling Nextel Brazil to America Movil, to wind up company</a></h4><ul>   <li>NII Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>) is <font color=\"red\">down 25.7%</font> premarket following <a href=\"https://seekingalpha.com/news/3443488-nii-holdings-reports-q4-results\" target=\"_blank\">Q4 earnings</a> where the company also announced it was selling Nextel Brazil (its last key operating asset) to America Movil (NYSE:<a href='https://seekingalpha.com/symbol/AMX' title='América Móvil, S.A.B. de C.V.'>AMX</a>).</li>    <li>NII will sell its 70% interest in the unit via the sale of one of its Luxembourg-based subsidiaries.</li>    <li>AI Brazil Holdings, owner of the other 30%, is also selling its stake to America Movil, which will become sole owner of Nextel Brazil for $905M less net debt.</li>    <li>The deal is the \"culmination of an extensive multi-year process to pursue a strategic path for Nextel Brazil and provides our best opportunity to monetize our remaining operating assets in light of the competitive landscape in Brazil and long-term need to raise significant capital to fund business operations, debt service and capital expenditures necessary to remain competitive in the future,\" says NII CFO Dan Freiman.</li>    <li>The board has approved a plan to wind up NII after the deal closes, leaving an estimated $1.00-$1.50/share to be distributed to stockholders from the transaction.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443604\" data-linked=\"NII selling Nextel Brazil to America Movil, to wind up company\" data-tweet=\"$NIHD $AMX - NII selling Nextel Brazil to America Movil, to wind up company https://seekingalpha.com/news/3443604-nii-selling-nextel-brazil-to-america-movil-to-wind-up-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3443604-nii-selling-nextel-brazil-to-america-movil-to-wind-up-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443600\" data-ts=\"1552915150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APVO\" target=\"_blank\">APVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443600-aptevo-therapeutics-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptevo Therapeutics beats on revenue</a></h4><ul><li>Aptevo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/APVO' title='Aptevo Therapeutics Inc.'>APVO</a>): FY GAAP EPS of -$2.39.</li><li>Revenue of $23.07M (+57.4% Y/Y) <font color=\"green\">beats by $0.07M</font>.</li><li>Shares <font color=\"green\">+4.27%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17446989-aptevo-therapeutics-reports-2018-financial-results-provides-business-update\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443600\" data-linked=\"Aptevo Therapeutics beats on revenue\" data-tweet=\"$APVO - Aptevo Therapeutics beats on revenue https://seekingalpha.com/news/3443600-aptevo-therapeutics-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443600-aptevo-therapeutics-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443598\" data-ts=\"1552915008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443598-nihd-ll-and-arpo-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NIHD, LL and ARPO among premarket losers</a></h4><ul><li>Aerpio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARPO' title='Aerpio Pharmaceuticals, Inc.'>ARPO</a>) <font color=\"red\">-64%</font> after lead candidate <a href=\"https://seekingalpha.com/news/3443520-aerpio-pharmas-lead-candidate-flunks-mid-stage-study\" target=\"_blank\">flunks</a> mid-stage study.</li><li>NII Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a>) <font color=\"red\">-24%</font> on <a href=\"https://seekingalpha.com/news/3443488-nii-holdings-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li><li>PolarityTE (NASDAQ:<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a>) <font color=\"red\">-23%</font> on <a href=\"https://seekingalpha.com/news/3443548-polarityte-reports-2m-results\" target=\"_blank\">reporting</a> 2M results.</li><li>vTv Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics Inc.'>VTVT</a>) <font color=\"red\">-21%</font>.</li><li>Teligent (NASDAQ:<a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a>) <font color=\"red\">-14%</font> on <a href=\"https://seekingalpha.com/news/3443538-teligent-misses-0_15-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3443565-soleno-therapeutics-reports-q4-resultsc\" target=\"_blank\">Q4 earnings</a>.</li><li>Lumber Liquidators Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3443500-lumber-liquidators-beats-0_01-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Globus Maritime Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>) <font color=\"red\">-11%</font>.</li><li>Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/news/3443563-tonix-pharmaceuticals-eps-6_10\" target=\"_blank\">Q4 earnings</a>.</li><li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>) <font color=\"red\">-5%</font> on <a href=\"https://seekingalpha.com/news/3443561-overstock-com-misses-0_61-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443598\" data-linked=\"NIHD, LL and ARPO among premarket losers\" data-tweet=\"$ARPO $NIHD $PTE - NIHD, LL and ARPO among premarket losers https://seekingalpha.com/news/3443598-nihd-ll-and-arpo-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3443598-nihd-ll-and-arpo-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443596\" data-ts=\"1552914949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZRX\" target=\"_blank\">AZRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443596-azurrx-up-20-premarket-on-positive-ms1819-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AzurRx up 20% premarket on positive MS1819 data</a></h4><ul><li>Thinly traded nano cap AzurRx BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/AZRX' title='AzurRx BioPharma, Inc.'>AZRX</a>) is up <font color=\"green\">20% </font>premarket on increased volume on the heels of <a href=\"https://seekingalpha.com/pr/17446592-azurrx-biopharma-announces-presentation-positive-phase-ii-data-ms1819-sd-chronic-pancreatitis\" target=\"_blank\">positive results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03481803?lead=azurrx&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 clinical tria</a>l evaluating lead drug MS1819-SD in chronic pancreatitis patients with exocrine pancreatic insufficiency. The data are being presented at Digestive Disease Week in San Diego.</li><li>Final results showed a favorable safety profile while the highest dose cohort showed statistically significant and clinically meaningful increases in the <a href=\"https://emedicine.medscape.com/article/2121028-workup\" target=\"_blank\">coefficient of fat absorption</a> &#40;CFA&#41; from baseline (the study was not powered for efficacy, though). Specifically, the mean increase in CFA in this group was 21.8%.</li><li>CFA is a standard used to measure dietary fat absorption and the effectiveness of pancreatic enzyme replacement therapy.</li><li>MS1819 is an orally available recombinant lipase derived from the yeast <em>Yarrowia Lipolytica</em>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443596\" data-linked=\"AzurRx up 20% premarket on positive MS1819 data\" data-tweet=\"$AZRX - AzurRx up 20% premarket on positive MS1819 data https://seekingalpha.com/news/3443596-azurrx-up-20-premarket-on-positive-ms1819-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3443596-azurrx-up-20-premarket-on-positive-ms1819-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443590\" data-ts=\"1552913982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443590-tonix-pharma-down-8-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma down 8% on Q4 results</a></h4><ul><li>Tonix Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <a href=\"https://seekingalpha.com/pr/17446667-tonix-pharmaceuticals-reports-fourth-quarter-full-year-2018-financial-results-operational\" target=\"_blank\">Q4 results</a>: Revenues: $0; R&amp;D Expense: $5.1M (+41.7%); SG&amp;A: $2.6M (+36.8%); Net Loss: ($10.9M) (-98.2%); Loss Per Share: ($6.10) (+13.7%); Quick Assets: $25M (-2.0%).</li><li>Shares are down <font color=\"red\">8%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443563-tonix-pharmaceuticals-eps-6_10\" target=\"_blank\">Tonix Pharmaceuticals EPS of -$6.10</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443590\" data-linked=\"Tonix Pharma down 8% on Q4 results\" data-tweet=\"$TNXP - Tonix Pharma down 8% on Q4 results https://seekingalpha.com/news/3443590-tonix-pharma-down-8-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443590-tonix-pharma-down-8-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443587\" data-ts=\"1552913730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUN\" target=\"_blank\">HUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443587-huntsman-sees-q1-adjusted-ebitda-falling-10-vs-prior-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntsman sees Q1 adjusted EBITDA falling 10% vs. prior quarter</a></h4><ul><li>Huntsman (NYSE:<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a>) <font color=\"red\">-1.6%</font> pre-market after <a href=\"https://seekingalpha.com/pr/17446389-huntsman-updates-first-quarter-2019-outlook\" target=\"_blank\">warning</a> it expects Q1 adjusted EBITDA to come in ~10% below Q4 2018.</li><li>HUN guides Q1 results in its polyurethanes segment - the company's largest unit - \"a bit softer than previously expected due to overall softer volumes,\" as the business is seeing improving trends in China but are more than offset by a slower than expected seasonal pickup in construction-related markets and lower demand in automotive in North America, and  softer demand patterns across most of its major European markets,  including automotive.</li><li>HUN also expects Q1 performance products results will come in flat to down from Q4 2018, vs. its previous guidance of flat to up, while the advanced materials segment shows similar pockets of softness, such as in construction and coatings, but Q1 results are seen rising modestly from Q4 2018, which is roughly in line with previous expectations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443587\" data-linked=\"Huntsman sees Q1 adjusted EBITDA falling 10% vs. prior quarter\" data-tweet=\"$HUN - Huntsman sees Q1 adjusted EBITDA falling 10% vs. prior quarter https://seekingalpha.com/news/3443587-huntsman-sees-q1-adjusted-ebitda-falling-10-vs-prior-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3443587-huntsman-sees-q1-adjusted-ebitda-falling-10-vs-prior-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443585\" data-ts=\"1552913486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OSTK\" target=\"_blank\">OSTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443585-overstock-to-revert-to-philosophy-of-profitability\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Overstock to revert to &quot;philosophy of profitability&quot;</a></h4><ul><li>Overstock.com (NASDAQ:<a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>)<font color=\"red\"> sinks 5.4%</font> in premarket trading after CEO and Founder Patrick M. Byrne says the company's retail arm lost money in FY2018 because he \"gunned things in an attempt to create a conventional high-growth/money losing e-commerce business.\"</li><li>Says company is reverting back to a \"philosophy of profitability on which we built Overstock,\" saying that the losses were \"nauseating.\"</li><li>Pledges to return retail business to profitability in 2019, targeting a minimum positive $10M operating cash flow for 2019.</li><li>Q4 loss per share of $1.39 vs. loss of $3.72 in the year-ago quarter.</li><li>Q4 total net revenue of $452.5M slipped from $456.3M a year earlier.</li><li>Q4 retail pretax loss of $27.7M increased from a loss of $17.6M a year earlier, while tZERO pretax loss of $12.6M swelled from a loss of $3.47M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443561-overstock-com-misses-0_61-misses-revenue\" target=\"_blank\">Overstock.com misses by $0.61, misses on revenue</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443585\" data-linked=\"Overstock to revert to &quot;philosophy of profitability&quot;\" data-tweet=\"$OSTK - Overstock to revert to &quot;philosophy of profitability&quot; https://seekingalpha.com/news/3443585-overstock-to-revert-to-philosophy-of-profitability?source=tweet\" data-url=\"https://seekingalpha.com/news/3443585-overstock-to-revert-to-philosophy-of-profitability\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443584\" data-ts=\"1552913470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNTA\" target=\"_blank\">MNTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443584-btig-likes-arcus-bio-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BTIG likes Arcus Bio in premarket analyst action</a></h4><ul><li>Momenta Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a>) initiated with Neutral rating at BTIG Research.</li><li>Arcus Biosciences (NYSE:<a href='https://seekingalpha.com/symbol/RCUS' title='Arcus Biosciences, Inc.'>RCUS</a>) initiated with Buy rating and $20 (71% upside) price target at BTIG.</li><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>) upgraded to Equal Weight with a $28 price target at Morgan Stanley. Shares up <font color=\"green\">1%</font> premarket.</li><li>Health Insurance Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations, Inc.'>HIIQ</a>) upgraded to Buy with a $45 (32% upside) price target at B. Riley FBR. Shares up <font color=\"green\">6% </font>premarket.</li><li>DENTSPLY SIRONA (NASDAQ:<a href='https://seekingalpha.com/symbol/XRAY' title='DENTSPLY SIRONA Inc.'>XRAY</a>) upgraded to Outperform at William Blair. Shares up <font color=\"green\">1%</font> premarket.</li><li>BioScrip (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a>) downgraded to Equal Weight with a $3.50 (26% upside) price target at Stephens.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) downgraded to Neutral at Credit Suisse.</li><li>Tetraphase Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals, Inc.'>TTPH</a>) downgraded to Hold at Gabelli. Shares down <font color=\"red\">1%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443584\" data-linked=\"BTIG likes Arcus Bio in premarket analyst action\" data-tweet=\"$MNTA $RCUS $EXEL - BTIG likes Arcus Bio in premarket analyst action https://seekingalpha.com/news/3443584-btig-likes-arcus-bio-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3443584-btig-likes-arcus-bio-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443580\" data-ts=\"1552913329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWL\" target=\"_blank\">NWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443580-newell-brands-unloads-process-solutions-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newell Brands unloads Process Solutions Business</a></h4><ul> <li>Newell Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a>) strikes a deal to sell its Process Solutions Business to PE firm One Rock       Capital Partners.</li><li>The after-tax proceeds for the divestiture are anticipated to be $500M.</li><li>The deal is expected to close in Q2.</li><li>NWL  <font color=\"green\">+1.16%</font> premarket to  $15.74.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17446763-newell-brands-announces-agreement-sell-process-solutions-one-rock-capital-partners-llc\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443580\" data-linked=\"Newell Brands unloads Process Solutions Business\" data-tweet=\"$NWL - Newell Brands unloads Process Solutions Business https://seekingalpha.com/news/3443580-newell-brands-unloads-process-solutions-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3443580-newell-brands-unloads-process-solutions-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>105&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443572\" data-ts=\"1552912597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLGT\" target=\"_blank\">TLGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443572-teligent-down-14-on-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teligent down 14% on Q4 results</a></h4><ul><li>Teligent (<a href='https://seekingalpha.com/symbol/TLGT' title='Teligent, Inc.'>TLGT</a>) <a href=\"https://seekingalpha.com/pr/17446591-teligent-inc-announces-fourth-quarter-year-end-2018-results\" target=\"_blank\">Q4 results</a>: Revenues: $16.8M (+13.5%).</li><li>Net Loss: ($14.4M) (-136.1%); Loss Per Share: ($0.27) (-145.5%); Non-GAAP Loss Per Share: ($0.18) (200.0%); Non-GAAP Net Loss: ($9.8M).</li><li><strong>2019 Guidance</strong>: Revenue: double digit top line percentage growth with revenues in excess of $72.5M.</li><li>Shares are down <font color=\"red\">14%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443572\" data-linked=\"Teligent down 14% on Q4 results\" data-tweet=\"$TLGT - Teligent down 14% on Q4 results https://seekingalpha.com/news/3443572-teligent-down-14-on-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3443572-teligent-down-14-on-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443571\" data-ts=\"1552912405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDS\" target=\"_blank\">PDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443571-precision-drilling-to-exit-mexico-sale-of-five-drilling-rigs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Precision Drilling to exit Mexico with sale of five drilling rigs</a></h4><ul><li>Precision Drilling (NYSE:<a href='https://seekingalpha.com/symbol/PDS' title='Precision Drilling Corporation'>PDS</a>) <font color=\"red\">-2.6%</font> pre-market after announcing deals to <a href=\"https://seekingalpha.com/pr/17446391-precision-drilling-announces-asset-divestitures-senior-note-redemption-provides-international\" target=\"_blank\">divest its five Mexico based drilling rigs</a> and ancillary equipment for $48M.</li><li>To date, PDS says it has received $30M for the sale of three drilling rigs with the balance due upon  delivery of the fourth and fifth rigs in March and April.</li><li>PDS says it also closed a deal to sell its Terra Water Systems water treatment business for an  undisclosed sum.</li><li>The company continues to explore sales of other non-core assets and businesses to focus on its land drilling business and efficiency driven technology  initiatives.</li><li>tPDS also says it signed three-year contract renewals for two rigs in Saudi Arabia, effective March 1.</li></ul><div class=\"tiny-share-widget\" data-id=\"3443571\" data-linked=\"Precision Drilling to exit Mexico with sale of five drilling rigs\" data-tweet=\"$PDS - Precision Drilling to exit Mexico with sale of five drilling rigs https://seekingalpha.com/news/3443571-precision-drilling-to-exit-mexico-sale-of-five-drilling-rigs?source=tweet\" data-url=\"https://seekingalpha.com/news/3443571-precision-drilling-to-exit-mexico-sale-of-five-drilling-rigs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443569\" data-ts=\"1552912234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QD\" target=\"_blank\">QD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443569-qudianplus-2_9-after-q4-beats-reaffirms-2019-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qudian +2.9% after Q4 beats, reaffirms 2019 guidance</a></h4><ul><li>Qudian (NYSE:<a href='https://seekingalpha.com/symbol/QD' title='Qudian Inc.'>QD</a>)<font color=\"green\"> jumps 2.9%</font> after <a href=\"https://seekingalpha.com/pr/17446351-qudian-inc-reports-fourth-quarter-full-year-2018-unaudited-financial-results\" target=\"_blank\">Q4 EPS </a>of 37 cents beat the average analyst estimate of 33 cents</li><li>Reaffirms 2019 adjusted net income guidance of RMB 3.5B, excluding non-operating costs and charges.</li><li>Q4 total revenue of RMB 1.80B ($262.3M) vs. RMB 1.49B in the year-ago quarter.</li><li>Total outstanding loan balance as of Dec. 31, 2018 increased 70% to RMB 19.0B from Dec. 31, 2017.</li><li>Outstanding loan balance that Qudian collaborates with financial institutions increased to RMB 22.0B by March 15, 2019.</li><li>M1+ delinquency rate by vintage for loans generated since Jan. 1, 2018 slightly increased to 2.5% through the end of 2018, as a result of longer loan tenure.</li><li>Q4 net income of RMB 767.5M, or RMB 2.52 (37 cents) per ADS vs. RMB 1.67 a year ago.</li><li>Q4 non-GAAP net income of RMB 767.5M, or RMB 2.56 per share, vs. RMB 540.1M, or RMB 1.73 per share.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3443486-qudian-beats-0_04-misses-revenue\" target=\"_blank\">Qudian beats by $0.04, misses on revenue</a> (March 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3443569\" data-linked=\"Qudian +2.9% after Q4 beats, reaffirms 2019 guidance\" data-tweet=\"$QD - Qudian +2.9% after Q4 beats, reaffirms 2019 guidance https://seekingalpha.com/news/3443569-qudianplus-2_9-after-q4-beats-reaffirms-2019-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3443569-qudianplus-2_9-after-q4-beats-reaffirms-2019-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443567\" data-ts=\"1552912120\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443567-piper-jaffray-expects-chipotle-recovery-to-continue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray expects Chipotle recovery to continue</a></h4><ul> <li>Piper Jaffray <a href=\"https://www.cnbc.com/2019/03/18/calls-of-the-day-facebook-dollar-general-johnson-controls-chipotle--more.html\" target=\"_blank\">lifts</a> its price target on Chipotle (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) to <a href=\"https://www.cnbc.com/2019/03/18/calls-of-the-day-facebook-dollar-general-johnson-controls-chipotle--more.html\" target=\"_blank\">$725</a> from $661.</li> <li>\"Chipotle remains our top recovery investment recommendation and we have a high degree of conviction that current strategic initiatives can continue to generate improving fundamentals,\" writes the PJ analysts team.</li> <li>\"As the company progresses through its recovery process we believe the conversation (from a stock perspective) eventually shifts to one that focuses on identifying incremental strategies to maximize shareholder value.\"</li> <li>Piper also teases the potential of Chipotle transforming its international store base into a growing franchise business, a scenario that it sees unlocking incremental profitability of $2 to $5 per share in earnings power.</li> <li>Shares of Chipotle are <font color=\"green\">up 0.55%</font> to $642.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3443567\" data-linked=\"Piper Jaffray expects Chipotle recovery to continue\" data-tweet=\"$CMG - Piper Jaffray expects Chipotle recovery to continue https://seekingalpha.com/news/3443567-piper-jaffray-expects-chipotle-recovery-to-continue?source=tweet\" data-url=\"https://seekingalpha.com/news/3443567-piper-jaffray-expects-chipotle-recovery-to-continue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443563\" data-ts=\"1552911598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443563-tonix-pharmaceuticals-eps-of-6_10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharmaceuticals EPS of -$6.10</a></h4><ul><li>Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>): Q4 EPS of -$6.10 may not be comparable to consensus of -$3.90.</li><li>Cash and cash equivalents of $25M</li><li>Shares <font color=\"green\">+1.05%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17446667-tonix-pharmaceuticals-reports-fourth-quarter-full-year-2018-financial-results-operational\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3443563\" data-linked=\"Tonix Pharmaceuticals EPS of -$6.10\" data-tweet=\"$TNXP - Tonix Pharmaceuticals EPS of -$6.10 https://seekingalpha.com/news/3443563-tonix-pharmaceuticals-eps-of-6_10?source=tweet\" data-url=\"https://seekingalpha.com/news/3443563-tonix-pharmaceuticals-eps-of-6_10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3443560\" data-ts=\"1552911380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IR\" target=\"_blank\">IR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3443560-wells-fargo-downgrades-ingersoll-rand-to-market-perform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo downgrades Ingersoll-Rand to Market Perform</a></h4><ul><li>\"At $106 (as of 03/15 close), the stock appears to be priced for superb execution in F'19, in our view... Our bull bear scenario indicates risk reward is <a href=\"https://www.cnbc.com/2019/03/18/calls-of-the-day-facebook-dollar-general-johnson-controls-chipotle--more.html\" target=\"_blank\">skewed</a> to the downside.\"</li><li>\"1) Expectations are at cycle high - 70% of the street has a buy on IR \u2013 highest since 2012... 2) C-HVAC growth expectations are above trend... 3) Any missteps likely costly for IR. Given high expectations, any shortfall in resi would be considered share loss to the re-emerging peer LII.... 4) Industrial order growth moderated in 2018 vs expectations for a pickup in momentum... 5) NTM FCF yield is slightly below last 5 yr trend (5.6% now vs 6.5% average the last few years. NTM FCF yield is also lower vs peers like JCI (6% IR vs 8% JCI).\"</li><li><a href='https://seekingalpha.com/symbol/IR' title='Ingersoll-Rand Plc'>IR</a> <font color=\"red\">-0.3%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3443560\" data-linked=\"Wells Fargo downgrades Ingersoll-Rand to Market Perform\" data-tweet=\"$IR - Wells Fargo downgrades Ingersoll-Rand to Market Perform https://seekingalpha.com/news/3443560-wells-fargo-downgrades-ingersoll-rand-to-market-perform?source=tweet\" data-url=\"https://seekingalpha.com/news/3443560-wells-fargo-downgrades-ingersoll-rand-to-market-perform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}